

## CURRICULUM VITAE

**Diana I. Brixner, R.Ph., Ph.D., FAMCP**

30 South 2000 East, Room 4781

Salt Lake City, UT 84112

801-581-3182 (phone) 801-587-7923 (fax)

E-Mail: [diana.brixner@utah.edu](mailto:diana.brixner@utah.edu)

### **I. EDUCATION**

- 2015 Certificate Introduction to Health Technology, University for Health Sciences, Medical Informatics and Technology, Hall in Tyrol, Austria
- 2013 Certificate Winter School in Clinical Epidemiology, University of Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria
- 2010 Certificate Modeling Approaches for Health Technology Assessment: A Practical Hands-On Workshop, University of Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
- 1987 Ph.D. University of Utah (Medicinal Chemistry)
- 1982 B.S. University of Rhode Island (Pharmacy)

### **II. PROFESSIONAL APPOINTMENTS**

- 2019 – Present Associate Member, Huntsman Cancer Institute Cancer Control and Population Sciences Research Program
- 2002 - Present Professor, Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah
- 2002 - Present Executive Director of Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, Utah
- 2016 - Present Adjunct Professor, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah
- 2017 - Present Adjunct Professor, Department of Pediatrics, Division of Clinical Pharmacology, University of Utah, Salt Lake City, Utah
- 2011 – Present Associated Researcher, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria
- 2012 – 2018 Director of Outcomes Personalized Health Program, University of Utah, Salt Lake City, Utah
- 2002 – 2015 Chair, Professor, Department of Pharmacotherapy
- 2001 – 2002 Executive Director, National Managed Care Accounts, U.S. Commercial Operations, Novartis Pharmaceuticals, East Hanover, New Jersey (Leadership Development)
- 1999 – 2001 Regional Director U.S. Sales, Novartis Pharmaceuticals, East Hanover, New Jersey (Leadership Development)
- 1996 – 1999 Executive Director and Vice President, Health Care Management US Commercial Operations, Novartis Pharmaceuticals, East Hanover, New Jersey
- 1995 – 1996 Director, Pharmaceutical Outcomes Research US Policy and Business Development, Ciba Pharmaceuticals, Summit, New Jersey
- 1994 – 2002 Adjunct Faculty Member, Philadelphia College of Pharmacy and Science, Philadelphia, Pennsylvania
- 1993 – 1995 Associate Director Outcomes Research Management, SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania

1992 – 1993	Medical Associate, Kaiser Permanente and National Accounts & Professional Relations, SmithKline Beecham Pharmaceuticals, Seattle, Washington
1990 – 1992	Regional Medical Associate, SmithKline Beecham Pharmaceuticals, Seattle, Washington
1989 – 1990	Marketing Services Manager, NeoRx Corporation, Seattle, Washington
1987 – 1989	Research Scientist, NeoRx Corporation, Seattle, Washington

### **III. HONORS AND DISTINCTIONS**

#### **A. Awards for Research, Teaching or Service**

2018	Top 10 Semi-Finalist out of 152 entries, “Leveraging Value to Convert Healthcare Premiums to Income,” American Dream Ideas Challenge, November 29, 2018, University of Utah.
2018	Nomination for “Teacher of the Year” by P3 Class for 2017-2018
2018	Nomination for “Teacher of the Year” by P4 Class for 2017-2018
2014	Fellow of the Academy of Managed Care Pharmacy
2013	University of Rhode Island, College of Pharmacy Distinguished Alumnus Award
2011	Academy of Managed Care Pharmacy Board of Directors Service Award 2009-2010
2009	International Society for Pharmacoeconomics and Outcomes Research Presidential Service Award 2006-2008
2007	Pruitt-Schutte Student Business Plan Competition Certificate of Achievement, National Community Pharmacists Association
2007	National Community Pharmacists Association Top Ten Business Plan Award Student Mentor
2007	American Association of Colleges of Pharmacy Walmart Scholarship Award Mentorship
2006	American Foundation of Pharmaceutical Education (AFPE) Gateway to Research Scholarship Award Mentorship
2006	Merck Leadership Service Award, Utah Pharmacists Association
2003	Journal of Managed Care Pharmacy Award for Excellence Judging Panel
2001	University of Utah, College of Pharmacy Distinguished Alumnus Award
1999	Organizational Contributor Award for the 2nd Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research
1998	Novartis Pioneer Award

#### **B. Appointments to Editorial, Professional or Scientific Boards**

2019 – 2021	Director of the Board, BBCIC
April 2018 – 2019	Chair, BBCIC
2017-2018	President AMCP
2016 - Present	AMCP Board of Directors
2015 – Present	Partner, Global Initiative for Translational Health Economics (GITHE)
2015 – Present	External Advisory Board, Hutchinson Institute for Cancer Outcomes Research
2010 – Present	Editorial Board, American Health & Drug Benefits
2008 – Present	Editorial Board, Pharmacoeconomics and Outcomes Research
2009-2010	Academy of Managed Care Pharmacy Board of Directors
2002 – 2015	Board Member, Utah Poison Control Center
2002 – 2006	Board Member, Utah Pharmacists Association

2008 – 2009	Chair, Scientific Board, International Society for Pharmacoeconomics and Outcomes Research Serbian Chapter
2006 – 2009	Board Member, International Society for Pharmacoeconomics and Outcomes Research
1998 – 2005	Editorial Board for Journal of Managed Care Pharmacy
1998 – 2000	Executive Board Member, International Society for Pharmacoeconomics and Outcomes Research

### **C. Appointments to National and International Committees**

2017-2019	Member, ISPOR Marilyn Dix Smith Leadership Award Committee
2015 – Present	International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Real World Data Task Force Member
2014 – Present	Academy of Managed Care Pharmacy (AMCP) Format Executive Committee
2013 – Present	Patient Centered Research for Outcomes Effectiveness and Measurement (PROEM) External Advisory Committee
2013 – 2015	Academy of Managed Care Pharmacy (AMCP) Program Planning and Development Committee
2013 – 2015	Academy of Managed Care Pharmacy (AMCP) Educational Affairs Committee
2011 – Present	International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Vision 2020 Communication Work Group
2011 – Present	Clinical and Translational Science Award Program (CTSA) Comparative Effectiveness Key Function Committee Methods Workgroup 2011
2011 – Present	Member, American Association of Colleges of Pharmacy (AACP) Research and Graduate Education Advisory Committee
2010 – 2018	Ad Hoc Member, VRx P& T, P&T Committee
2010 – Present	Health Policy Council International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
2009 – Present	ISPOR Health Policy Advisory Council
2003 – 2004	Member, Utah Heart Association, Education Committee
2003 – 2005	Member, AcademicKeys, Who's Who in Pharmaceutical Sciences Education
2005 – 2008	Academy of Managed Care Pharmacy, Pharmacy Schools Committee
2003 – 2008	Ad Hoc Member, RxAmerica, P & T Committee
2004 – 2006	Chair, International society for Pharmacoeconomics and Outcomes Research, Managed Care Special Interest Group
2004 – 2005	Advisor, Academy of Managed Care Pharmacy (AMCP), Committee for Version 2.1 of AMCP Format Dossier
2004 – 2005	Member, American Council on Headache Education, Governing Council
2003 – 2005	Member, Utah Department of Health, Utah Pharmacy Data Access Committee
1999 – 2000	Member, Pharmaceutical Manufacturer's Association of America, Health Outcomes Working Group Committee
1997 – 1998	Chair, International Society for Pharmacoeconomics and Outcomes Research, (ISPOR) Institutional Council

### **D. Memberships in National and International Societies**

2009 – 2010	Member, Health Technology Assessment International (HTAi)
2002 – 2015	Member, American Association of Colleges of Pharmacy
2002 – 2008	Member, American Society of Health System Pharmacists

2002 – 2008	Member, Utah Pharmacists Association
1996 – Present	Founding Member, Academy of Managed Care Pharmacy
1995 – Present	Founding Member, International Society for Pharmacoeconomics and Outcomes Research

#### **E. Offices Held in Professional Organizations**

2016 - 2017	President Elect, Academy of Managed Care Pharmacy
2009 – 2011	Academy of Managed Care Pharmacy Director
2006 – 2009	President-Elect, President, and Past-President, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2006 – 2007	Utah Pharmacists Association Vice President

#### **IV. SERVICE**

##### **A. Department Committees**

2017 – Present	Search Committee Chair, Tenure Track Faculty
2017 – Present	Director and Chair, Graduate Programs Committee
2004 – Present	Committee Member for Graduate Programs
2005 – 2006	Committee Member, Faculty Assessment Task Force
2004 – 2005	Committee Member, Research Track Guidelines Committee
2002 – 2003	Committee Member, Clinical Retention and Promotion Advisory Committee

##### **B. College Committees**

2016 – Present	Scholarly Oversight Committee, Clinical Pharmacology Fellowship Program
2015 – 2016	Diversity and Inclusion Committee
2015 – 2016	Research and Graduate Programs Committee
2012 – 2013	Research and Graduate Affairs Committee
2003 – 2015	Member, College of Pharmacy College Executive Committee
2003 – 2015	Member, College of Pharmacy Space Committee
2003 – 2006	Chair, College of Pharmacy Continuing Education Committee

##### **C. Health Sciences Center Committees**

2018 – Present	Member, University of Utah Health Plans PT Committee
2018 – 2018	Member, Cystic Fibrosis Therapeutics Committee
2017 – Present	Member, Academic Integration Committee
2013 – Present	Center for Clinical and Translational Science (CCTS) Executive Steering Committee
2013 – 2014	Institute for Health Care Transformation Committee
2012 – Present	Health System Innovation and Research Program/Population Health Science (HSIR/PHS) Steering Committee
2012 – 2014	Search Committee Health System Innovation and Research Director
2011 – 2012	Planning Committee Member, Executive Board Health Care Reform and Health Services Research Symposium 2012, Primary Care Research Network
2011 – 2014	Member, University of Utah Personalized Health Care Program Executive Advisory Committee
2011 – 2013	Member, Health Services Research Advisory Committee
2009 – 2011	Member, Center on Aging
2005 – Present	Member, Huntsman Cancer Center Research Group

2003 – 2008	Member, Utah Primary Care Research Network, Steering Committee
2003 – 2006	Member, Center of Excellence in Women’s Health Research Group
2008 – 2009	Member, Search Committee College of Pharmacy, Dean of College of Pharmacy
2003 – 2008	Member, Primary Care Research Center, Steering Committee
2003 – 2004	Member, Search Committee Health Services, Vice President of Quality
2003 – 2004	Member, School of Medicine Search Committee, Internal Medicine Department

**D. Reviewer for Publications – Ongoing Since:**

The Journal of Pediatrics 2016  
 Health Policy and Technology 2015  
 Diabetes, Obesity and Metabolism 2012  
 Journal of Medical Economics 2013  
 Diabetes Care 2010  
 Expert Review of Pharmacoeconomics and Outcomes Research 2010  
 BioMed Central 2009  
 The American Journal of Pharmacy Benefits 2009  
 Diabetes, Obesity, Metabolism 2009  
 Applied Clinical Informatics 2009  
 International Journal of Clinical Practice 2008  
 The Patient 2007  
 Expert Review of Pharmacoeconomics and Outcomes Research 2007  
 Managed Care Interface 2006  
 Value in Health 2005  
 Journal of Occupational and Environmental Medicine 2004  
 Clinical Therapeutics 2002  
 Current Medical Research and Opinion 2002  
 Journal of Managed Care Pharmacy 1998

**E. Panel Reviews**

A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information. Patient Centered Outcomes Research Translation Center (PCOR-TC). October 2017.

**V. TEACHING**

**A. Courses**

Spring 2019	PHARM 7762 Outcomes Clerkship – 2 students
Spring 2019	U.S. Health Care Policy – PHARM 7342
Spring 2018	Pharmacy & Therapeutics Committees Elective
11/20/2018	Foundations in Personalized Health Care - MDCRC 6150. Lecture Cost Effectiveness Research and Affordable Care
Fall 2018	Managed Care Elective – PHARM 7552
Fall 2018	PHARM 7762 Outcomes Clerkship – 1 student
Spring 2018	U.S. Health Care Policy – PHARM 7342
4/24/2017	Foundations in Personalized Health Care – MDCRC 6150. Lecture Future of Personalized Health Care [Panel Discussion]

4/10/2017	Foundations in Personalized Health Care – MDCRC 6150. Lecture Cost Effectiveness Research and Affordable Care
Fall 2017	PHARM 7762 Outcomes Clerkship – 1 student
Fall 2017	Managed Care Elective – PHARM 7552
Fall 2016	Research Seminar 1 – PCTH 7890. Lecture Large Databases for Outcomes Research
Fall 2016	Clinical Information Services, Real-World Evidence – PCTH 7413
4/25/2016	Foundations in Personalized Health Care – MDCRC 6150. Lecture Careers in Personalized Health Care [Open Discussion]
4/18/2016	Foundations in Personalized Health Care – MDCRC 6150. Lecture The Future of Personalized Health Care [Panel Discussion]
4/4/2016	Foundations in Personalized Health Care – MDCRC 6150. Lecture Affordable Personalized Health Care
Spring 2015	Multinational Health Care Policy PCTH 7115
4/29/2013	Application of Outcomes Research to Personalized Medicine -MDCRC 6150. Lecture Foundations in Personalized Health Care. [Panel Discussion]
4/1/2013	Application of Outcomes Research to Personalized Medicine -MDCRC 6150. Lecture Foundations in Personalized Health Care.
Fall 2012	Multinational Health Care Policy PCTH 7115
4/30/2012	Personalized Health Care Research Opportunities, Didactic Lecture -MDCRC 6150. Lecture
1/30/2012	Capstone lecture Pharmaceuticals HSP 5000: Health Society, and Policy Capstone, Didactic Lecture-Real World Data in Health Care Decision Making
Fall 2002–2015	Pharmacotherapy 7123: Pharmacy Management
Spring 2008–2009	Pharmacotherapy 7150: Outcomes Research Elective
2004–2006	Pharmacotherapy 7538: Outcomes Clerkship(6); 3 students
2005	Pharmacy Practice 5950: Special Problems(1) student

#### **B. Ph.D. Committees**

2015	Committee Member for Marisa Schauerhamer, University of Utah
2015	Chair for Tianze Jiao, University of Utah
2014	Committee Member for Kuan-Ling Kuo, University of Utah
2010	Committee Member for Sameer Ghate, University of Utah
2008	Committee Member for Carrie McAdam-Marx, University of the Sciences in Philadelphia
1994	Committee Member for Janeen Duchane, University of the Sciences in Philadelphia

#### **C. Master Thesis Committees**

2009	Committee Chair for Asha Krishnaraj, University of Utah
2009	Committee Chair for Dusica Tasic, University of Utah

#### **D. Fellowship Mentor Committees**

2017 – Present	Fellowship Mentor for Connor Willis, PharmD, Post Doctoral Fellow, PORC
2017 – Present	Fellowship Mentor for Jyothi Menon, PhD, Post Doctoral Fellow, PORC
2016 – 2018	Fellowship Mentor for Kibum Kim, PhD, Post Doctoral Fellow, PORC
2016 – 2018	Fellowship Mentor for Natalia Ruiz-Negrón, PharmD, Post Doctoral Fellow, PORC
2015 – 2017	Fellowship Mentor for Trang Au, PhD, Post Doctoral Fellow, PORC

2014 – 2016	Fellowship Mentor for Amy Sainski, PhD, Post Doctoral Fellow, PORC
2014 – 2016	Fellowship Mentor for Jordan King, PhD, Post Doctoral Fellow, PORC
2011 – 2012	Fellowship Mentor for Kim Saverno, PhD, Post Doctoral Fellow, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria
2011	Fellowship Committee for Kim Morley, MD, Huntsman Cancer Institute, School of Medicine, University of Utah
2010 – 2012	Fellowship Mentor for Brandon Bellows, PharmD, Post Doctoral Fellow, PORC
2003 – 2005	Fellowship Mentor for Joanne LaFleur, PharmD, MPH, Post Doctoral Fellow, PORC
2003 – 2005	Fellowship Mentor for Mei-Jen Ho, Pharm D, Post Doctoral Fellow, PORC
2003 – 2004	Fellowship Mentor for Qayim Said, PhD, Post Doctoral Fellow, PORC
2003 – 2004	Fellowship Mentor for Vijay Joish, BPharm, PhD, Post Doctoral Fellow, PORC

## VI. PUBLICATIONS

### A. Journal Articles: Peer-Reviewed Articles

#### 2019

1. Kim K, Unni S, **Brixner D**, Thomas SM, Olsen CJ, Sterling KL, Mitchell M, McAdam-Marx C. Longitudinal Changes in HbA1c Following Treatment Intensification After Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes. *Diabetes, Obesity and Metabolism* [accepted March 2019].
2. Kim K, Unni S, McAdam-Marx C, Thomas SM, Sterling KL, Olsen CJ, Johnstone B, Mitchell M, **Brixner D**. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents. *J Manag Care Spec Pharm*. 2019 Mar;25(3):314-322.
3. Chang A, Nelson R, **Brixner D**. Advancing Pharmacy Practice by Reducing Gaps in Pharmacogenetics Education. *Am J Health Syst Pharm*. 2019 Feb 9;76(5):320-326.
4. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, **Brixner DI**, Schiffman JD. Cost-Effectiveness of Early Cancer Surveillance for Patients with Li-Fraumeni Syndrome. *Pediatr Blood Cancer*. 2019 Feb 4:e27629. [Epub ahead of print]
5. **Brixner D**, Woodward T C, Seifter N, Biskupiak J, Marciniak M, Neumann P, Oderda G. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies. *J Manag Care Spec Pharm*, 2019 Feb;25(2):164-173.
6. **Brixner D**, Ermakova A, Xiong Y, Sieradzan R, Sacks N, Cyr P, Taylor SD. Clinical and Economic Outcomes Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-Bolus Insulin (MDI) Therapy: A Retrospective Cohort Study. *Clin Ther*. 2019 Jan 29. [Epub ahead of print]
7. Stenehjem DD, Au TH, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, **Brixner DI**. Immunotargeted Therapy in Melanoma: Patient, Provider Preferences, and Willingness to Pay at an Academic Cancer Center. *Melanoma Res*. 2019 Jan 25. [Epub ahead of print].

#### 2018

8. Inotai A, **Brixner D**, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, Yasmina A, Priohutomo S, Nemeth B, Wiyaya K, Zalo Z. Development of Multi-Criteria Decision Analysis (MCDA) Framework for Off-patent Pharmaceuticals – An Application on Improving Tender Decision Making in Indonesia. *BMC Health Serv Res*. 2018 Dec 29;18(1):1003.
9. Kim K, Magness J, Nelson R, Baron V, **Brixner D**. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients. *J Manag Care Spec Pharm*, 2018 Dec;24(12):1250-1259.
10. Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Németh B, Maniadakis N, **Brixner D**, Wijaya K, Kaló Z. Guidance Toward the Implementation of Multicriteria Decision Analysis Framework in Developing Countries. *Expert Rev Pharmacoecon Outcomes Res*. 2018 Dec;18(6):585-592.
11. Mistry R, Suri G, Young K, Hettle R, May JR, **Brixner D**, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA. Budget Impact of Including Ribociclib in Combination with Letrozole

on US Payer Formulary: First-line Treatment of Post-Menopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer. *Curr Med Res Opin*. 2018 Dec;34(12):2143-2150.

12. Oderda GM, Lawless GD, Wright GC, Nussbaum SR, Elder R, Kim K, **Brixner DI**. The Potential Impact of Monitoring Disease Activity Biomarkers on Rheumatoid Arthritis Outcomes and Costs. *Personalized Medicine. Per Med*. 2018 Jul 1;15(4):291-301.
13. Rohit Mistry, Jessica R. May, Gaurav Suri, Kate Young, **Diana Brixner**, Gary Oderda, Joseph Biskupiak, Derek Tang, Subrata Bhattacharyya, Dinesh Mishra, Devarshi Bhattacharyya, Anand A. Dalal. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. *J Manag Care Spec Pharm*. 2018 Jun;24(6):514-523.
14. **Brixner D**, Kaló Z, Maniadakis N, Kim K, Wijaya K. An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for Health Technology Assessment in Emerging Markets. *Value Health Reg Issues*. 2018 Mar 29;16:9-13.
15. Stenehjem D, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, **Brixner DI**. Impact of a Genetic Counseling Requirement Prior to Genetic Testing. *BMC Health Serv Res*. 2018 Mar 7;18(1):165.
16. Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, **Brixner DI**, Garrison LP, Murray MD. Nine Years of Comparative Effectiveness Research Education and Training: Initiative Supported by the PhRMA Foundation. *J Comp Eff Res*. 2018 Feb;7(2):167-175.

## 2017

17. Jahn B, Rochau U, Kurzhailer C, Hubalek M, Miksad R, Srocynski G, Paulden M, Bundo M, Stenehjem D, **Brixner D**, Krahn M, Siebert U. Personalized Treatment of Women with Early Breast Cancer: A Risk-Group Specific Cost-Effectiveness Analysis of Adjuvant Chemotherapy Accounting for Companion Prognostic Tests OncotypeDX and Adjuvant!Online. *BMC Cancer*, 2017 Oct 16; 17(1):685.
18. Berger ML, Sox H, Willke RJ, **Brixner DI**, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel Mullens C. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Value Health*. Sept. 2017; 20(8): 1003-1008.
19. Bellows BK, Sainski-Nguyen A, Olsen CJ, Boklage SH, Charland S, Mitchell MP, **Brixner DI**. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. *J Manag Care Spec Pharm*. Sept 2017;23(9):926-34.
20. **Brixner D**, Maniadakis N, Kalo Z, Hu S, Shen J, Wijaya K. Applying Multi-criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. *Value Health Reg Issues*, 2017 Sept;13:1-6.
21. Kong AM, Hurley D, Evans KA, **Brixner D**, Csoboth C, Visootsak J. A Retrospective, Longitudinal, Claims-Based Comparison of Concomitant Diagnoses Between Individuals With and Without Down Syndrome. *J Manag Care Spec Pharm*, 2017 Jul;23(7):761-770.
22. Tak CR, Job KM, Schoen-Genry K, Campbell SC, Carroll P, Costantine M, **Brixner D**, Birnbaum AK, Sherwin CMT. The Impact of Exposure to Antidepressant Medications during Pregnancy on Neonatal Outcomes: A Review of Retrospective Database Cohort Studies. *Eur J Clin Pharmacol*, 2017 Sep;73(9):1055-1069.

## 2016

23. **Brixner D**, Stenehjem DD, Ulrich C. Aspirin and Cancer Risk. *JAMA Oncol* 2016 Oct 1;2(10):1370-1371.
24. Kuo Kuan-Ling, **Brixner D**, Lipman A, Goodman M, Hung M, Odera G. Single- Versus Multiple – Drug Pharmacotherapy in the Management of Diabetic Painful Neuropathy. *J Pain Palliat Care Pharmacotherapy*. 2016 Sep;30(3):184-94.
25. Augustine J, Warholak TL, Hines LE, Sun D, Brown M, Hurwitz J, Taylor AM, **Brixner D**, Cobaugh DJ, Schlaifer M, Malone DC. Ability and Use of Comparative Effectiveness Research by P&T Committee Members and Support Staff: A 1-Year Follow-up. *J Manag Care Spec Pharm*. 2016 Jun;22(6):618-25.



26. Ben-Joseph R, Bell JA, **Brixner D**, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D. Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone. *J Manag Care Spec Pharm*. 2016 Apr;22(4):358-66.
27. Ruble JH, **Brixner D**. Pharmacy Expenditures for Children with Serious Chronic Illness. *JAMA*. 2016 Feb 16;315(7):706.
28. Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, **Brixner DI**. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. *Oncologist*. 2016 Feb;21(2):196-204.
29. Bress AP, King JB, **Brixner D**, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. *Pharmacotherapy*. 2016 Feb;36(2):174-86.
30. Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, Stevens V, **Brixner DI**, Stenehjem DD. BRCA Testing, Treatment Patterns and Survival in Platinum-Sensitive Recurrent Ovarian Cancer - An Observational Cohort Study. *J Ovarian Res*. 2016 Mar 22;9:18.
31. Kachroo S, Hamilton M, Liu X, Pan X, **Brixner D**, Marrouche N, Biskupiak J. Oral Anticoagulant Discontinuation in Patients with Nonvalvular Atrial Fibrillation. *Am J Manag Care*. 2016 Jan 1;22(1):e1-8.
32. **Brixner D**, Meltzer EO, Morland K, Carroll CA, Munzel U, Lipworth BJ. Implication of Alternative Minimal Clinically Important Difference Threshold Estimation Methods on Technology Assessment. *Int J Technol Assess Health Care*. 2016 Jan;32(6):371-375.
33. **Brixner D**, Biltaji E, Bress A, Unni S, ye X, Mamiya T, Ashcraft K, Biskupiak J. The effect of pharmacogenetics profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. *J Med Econ*. 2016;19:213-28.

## 2015

34. Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, **Brixner D**, Siebert U. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. *Leukemia Research and Treatment*. 2015;2015:982395.
35. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pagner K, Fehervary A, **Brixner D**, Siebert U. Systematic Overview of Cost-Effectiveness Thresholds in Ten Countries Across Four Continents. *J. Comp. Eff. Res*. 2015 4(5); 485-504.
36. Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, **Brixner D**. Value Assessment for Genetic Testing of Drug Variation in an Elderly Population. *Value Health*. 2015 Nov;18(7):A747.
37. Stenehjem D, Korytowsky B, Oderda G, Wanishayakorn T, Bauer H, **Brixner D**. Understanding the Impact of Patient and Physician Preferences in Personalized Treatment for Melanoma Using a Discrete Choice Experiment. *Value Health*. 2015 Nov;18(7):A469-70.
38. Rochau U, Vukicevic D, Schmidt S, Stenehjem D, **Brixner D**, Radich J, Gastl G, Siebert U. Cost-Effectiveness Analysis on Starting Patients with Chronic Myeloid Leukemia on a Highly Potent Tyrosine Kinase Inhibitor and Early Switching to Imatinib. *Value Health*. 2015 Nov;18(7):A462.
39. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, conrads-Frank A, Stenehjem D, **Brixner D**, Radich J, Gastl G, Siebert U. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. *Leuk Lymphoma*. 2015 Aug 56(8); 2315-25.
40. Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, **Brixner D**, Siebert U. The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. *Appl Health Econ Health Policy*. 2015 Aug; 13 Suppl 1:S21-33.
41. Kuo KL, Stenehjem D, Albright F, Ray S, **Brixner D**. Treatment Patterns and Outcomes in Patients with Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories. *J Natl Compr Cancer Netw*. 2015 Aug. 13(8); 987-94.
42. Unni S, White K, Goodman M, Ye X, Mavros P, Bash LD, **Brixner D**. Hypertension Control and Antihypertensive Therapy in Patients With Chronic Kidney Disease. *Am J Hypertens*. 2015 Jun;28(6); 814-22.

43. Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, **Brixner D**. Need for multicriteria evaluation of generic drug policies. *Value Health*. 2015 Mar;18(2): 346-51.

## 2014

44. McAdam-Marx C1, Bellows BK, Unni S, Mukherjee J, Wygant G, Iloeje U, Liberman JN, Ye X, Bloom FJ, **Brixner DI**. (2014) Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). *Int J Clin Pract*. 2014 Nov;68(11):1309-17.
45. Rochau U, Kluibenschaedl M, Stenehjem D, Kuo KL, Oderda G, **Brixner D**, Siebert U. Decision Analysis on the Cost-Effectiveness of Sequential Treatment Strategies for patients with Chronic Myeloid Leukemia in the United States. *Value Health*. 2014 Nov;17(7):A639.
46. Holtorf AP, Palacios D, **Brixner D**. Are Patient Reported Outcomes Relevant to Patients? Learnings from a Patient Advocate Survey. *Value Health*. 2014 Nov;17(7):A517.
47. Holtorf AP, Palacios D, **Brixner D**. The Role of Patients in Clinical Research and Evidence Based Decision Making as Reported via a Survey of Patient Advocates. *Value Health*. 2014 Nov;17(7):A435.
48. Stenehjem DD, Yoo M, Unni SK, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, **Brixner DI**. Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. *Breast Cancer* (Dove Med Press). 2014 Oct 29;6:169-77.
49. Tang DH, Warholak TL, Hines LE, Hurwitz J, Brown M, Taylor AM, **Brixner D**, Malone DC. Evaluation of Pharmacy and Therapeutic (P&T) Committee Member Knowledge, Attitudes and Ability Regarding the Use of Comparative Effectiveness Research (CER) in Health Care Decision-Making. *Res Social Adm Pharm*. 2014 Sep-Oct;10(5):768-80.
50. Stenehjem DD, Albright F, Kuo K-L, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, **Brixner DI**. (2014) Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. *J Natl Compr Canc Netw*. 2014 Aug;12(8):1113-21.
51. Rochau U, Sroczyński G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner D**, Radich J, Gastl G, Siebert U. (2014) Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. *Leuk Lymphoma*. 2014 Aug;55(8):1758-67.
52. McAdam-Marx C, Bellows BK, Unni S, Wygant G, Mukherjee J, Ye X, **Brixner DI**. (2014) Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. *J Manag Care Pharm*. 2014 Jul, 20(7): 691-700.
53. Oderda GM, Shiozawa A, Walsh M, Hess K, **Brixner DI**, Feehan M, Akhras K. (2014) Physician adherence to ACR gout treatment guidelines: perception versus practice. *Postgrad Med*. 2014 May, 126(3):257-67.
54. Rochau U, Schwarzer R, Jahn B, Sroczyński G, Kluibenschaedl M, Wolf D, Radich J, **Brixner D**, Gastl G, Siebert U. (2014) Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. *Appl Health Econ Health Policy*. 2014 Apr, 12(2):103-15.
55. Chen SY, Lee YC, Alas V, Greene M, Brixner D. (2014) Outcomes associated with nonconcordance to national kidney foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease. *Endocr Pract*. 2014 Mar, 20(3): 221-31.
56. Saverno K, Gothe H, Schuessel K, Biskupiak J, Schulz M, Siebert U, **Brixner D**. (2014) Consideration of international generic distribution policies on patient outcomes in the United States and Germany. *Die Pharmazie*. 2014 Mar, 69(3):238-40.
57. McAdam-Marx C, Mukherjee J, Bellows BK, Unni S, Ye X, Iloeje U, **Brixner DI**. (2014) Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. *Diabetes Res Clin Pract*. 2014 Mar, 103(3):402-11.

## 2013

58. Villa L, Warholak T, Hines L, Taylor A, Brown M, Hurwitz J, **Brixner DI**. (2013) Malone D. Health Care Decision Makers' Use of Comparative Effectiveness Research: Report from a Series of Focus Groups. *Journal of Managed Care Pharmacy*. 2013 Nov, 19(9) 745-54.
59. Biskupiak J, Ghate S, Jiao T, **Brixner DI**. (2013) Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. *Journal of Managed Care Pharmacy*. 2013 Nov, 19(9) 789-98.

60. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Beate J, Saverno K, **Brixner D**, Radich J, Gastl G, Siebert U. (2013) Medical decision analysis for first-line therapy of chronic myeloid leukemia.
  61. Blouin R, **Brixner DI**, Cutler S, Derendorf HC, Poloyak SM, Ellingrod Ringold VL, Schnellman RG, Swaan P, Lau YS. (2013) The Report of the 2012-2013 Research and Graduate Affairs Committee. *Am J Pharm Educ*. 2013 Oct 14, 77(8): s9.
  62. Dhamane A, Martin B, **Brixner DI**, Hudson T, Said Q. (2013) Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics. *Journal of Psychiatric Practice*. 2013 Sep, 19(5): 1-15.
  63. Goodman MJ, Ghate SR, Mavros P, Sen S, Marcus RL, Joy E, **Brixner DI**. (2013) Development of Practical Screening Tool to Predict Low Muscle Mass Using NHANES 1999-2004. *Journal of Cachexia Sarcopenia Muscle*. 2013 Sep, 4(3):187-97.
  64. **Brixner, DI**, Bron M, Bellows BK, Ye X, Yu J, Raparla S, Oderda GM. (2013) Evaluation of Cardiovascular Risk Factors, Events and Costs Across Four BMI Categories. *Obesity*. 2013 Jun, 21(6): 1284-92.
  65. Stanford JB, Martin JC, Gibson M, Birdsall E, **Brixner DI**. (2013) Use of Clomiphene Citrate in the University of Utah Community Clinics. *Journal of Reproductive Medicine*. 2013 May/June, 58(5-6): 229-33.
  66. Chen SY, Lee YC, Alas V, Greene M, **Brixner DI**. (2013) Outcomes Associated with Concordance of Oral Antidiabetic Drug Treatments to Prescribing Information in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Journal of Medical Economics*. 2013, 16(5): 586-95.
  67. Goodman MJ, **Brixner DI**. (2013) New Therapies for Treating Down Syndrome Require Quality of Life Measurement. *American Journal of Medical Genetics Part A*. 2013 Apr, 1(4): 639-41.
  68. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, **Brixner DI**. (2013) Association Between Second-generation Antipsychotics and Changes in Body Mass Index in Adolescents. *Journal of Adolescent Health*. 2013 Mar, 52(3): 336-43.
  69. Chen SY, Lee YC, Alas V, Greene M, **Brixner DI**. (2013) Outcomes Associated with Concordance of Oral Antidiabetic Drug Treatments to Prescribing Information in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Journal of Medical Economics*. 2013 Feb, 16(5): 586-95.
- 2012**
70. Holtorf A, **Brixner DI**, Bellows B, Keskinaslan A, Dye J, Oderda G. (2012) Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. *American Health and Drug Benefits*. 2012 Nov/Dec: 5(7): 428-438.
  71. Lau YS, Blouin R, **Brixner DI**, Crismon L, Cutler S, Ho R, Jusko W, Nahata M, Sorkness C, Torchilin VP, Wu-Pong S. (2013) Report of the 2011-2012 AACP Special Advisory Committee on Research and Graduate Education. *American Journal of Pharmaceutical Education*. 2012 Oct, 76(8): S14.
  72. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, **Brixner DI**. (2012) Predictors of Metabolic Parameter Monitoring in Adolescents on Antipsychotics in a Primary Care Setting. *Ment Health Fam Med*. 2012 Sept, 9(3):137-48.
  73. Saverno KR, Rochau U, Stenehjem DD, Morley K, Siebert U, **Brixner DI**. (2012) Application of Decision-analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. *Journal of Managed Care Pharmacy*. 2012 Jul/Aug, 18(6): 457-463.
  74. **Brixner DI**. (2012) This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? [Introduction] *Journal of Managed Care Pharmacy*. 2012 Jun, 18(5):S5.
  75. **Brixner DI**, Watkins J, Oderda G, Sifford-Wilson S, Biskupiak J, Dunn J, Holtorf A. (2012) This Drug May Work, But Is It Worth the Cost? Can Comparative Effectiveness Research Help Tame Rising Health Cost? *Journal of Managed Care Pharmacy*. 2012 Jun, 18(5):S6-19.
  76. Goodman, M, Durkin M, Forlenza J, Ye X, **Brixner DI**. (2012) Assessing Adherence-based quality measures in epilepsy. *International Journal for Quality in Health Care*. 2012 Jun, 24(3):293-300.
  77. **Brixner DI**, Oderda G. (2012) [Introduction] Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. *Journal of Managed Care Pharmacy*. 2012 May 18:(4a):S3-S4.

78. **Brixner DI**, Oderda G, Mohr P, Dubois R, Cannon HE. (2012) Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making. *Journal of Managed Care Pharmacy*. 2012 May, 18:(4a):S5-17.
79. Marcus RL, **Brixner DI**, Ghate S, Lastayo P. (2012) Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults. *Curr Gerontol Geriatr Res*. Epub 2012 Jan 23.

## 2011

80. Ghate SR, Biskupiak J, Ye X, Kwong WJ, **Brixner DI**. (2011) All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. *J Manag Care Pharm*. 2011 Nov, 17(9):672-84.
81. Kempf J, Buysman E, **Brixner DI**. (2011) Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. *American Health & Drug Benefits*. 2011 Sep/Oct, 4(6).
82. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, **Brixner DI**. (2011) All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm*. 2011 Sep, 17(7):531-46.
83. Ghate SR, Biskupiak JE, Ye X, Hagan M, Kwong WJ, Fox ES, **Brixner DI**. (2011) Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. *Ann Pharmacother*. 2011 Jun, 45(6):701-12.
84. Nelson RE, McAdam-Marx C, Evans ML, Ward R, Campbell B, **Brixner DI**, Lafleur J. (2011) Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme. *Appl Health Econ Health Policy*. 2011 May, 1:9(3):171-81.
85. LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, Nebeker J, **Brixner DI**, Silverman S. (2011) Clinical risk factors for fracture among postmenopausal patients at risk for fracture: A historical cohort study using electronic medical record data. *Journal of Bone and Mineral Metabolism*. 2011 Mar, 29(2):193.
86. McAdam-Marx C, Bouchard J, Aagren M, Conner C, **Brixner DI**. (2011) Concurrent Control of Blood Glucose, Body mass, and Blood Pressure in Patients with Type 2 Diabetes: An Analysis of Data From Electronic Medical Records. *Clinical Therapeutics*. 2011 Jan, 33(1): 110-120.

## 2010

87. Yu J, Smith K, **Brixner DI**. (2010) Cost-Effectiveness of Pharmacotherapy for the Prevention of Migraine: An Application of Markov Model. *CNS Drugs*. 2010 Aug, 24(8): 695-712.
88. **Brixner DI**, McAdam-Marx C, Ye X, Lau H, Munger M. (2010) Assessment of Time to Follow-up Visits in Newly-Treated Hypertensive Patients Using an Electronic Medical Record Database. *Current Med Research & Opinion*. 2010 Aug, 26(8): 1881-91.
89. McAdam-Marx C, Gaebler J, Bellows B, **Brixner DI**. (2010) Contemporary Management of Patients with Type 2 Diabetes. *Expert Rev. Cardiovasc. Ther*. 2010 Jun, 8(6): 767-770.
90. McAdam-Marx C, Yu J, Bouchard J, Aagren M, **Brixner DI**. (2010) Comparison of Daily Insulin Dose and Other Antidiabetic Medications Usage for Type 2 Diabetes Patients Treated with an Analog Basal Insulin. *Curr Med Res Opin*. 2010 Jan, 26(1): 191-201.
91. McAdam-Marx C, Field R, Metraux S, Moelter S, **Brixner DI**. (2010) Physician Utilization by Insurance Type in Youth with Type 2 Diabetes. *Am. J Manag Care*. 2010 Jan, 16(1): 55-64.

## 2009

92. **Brixner DI**, Ye X, Chu TC, Blumentals WA, Hassanein TI. (2009) Treatment Persistence in and Cost of Therapy for Patients with Chronic Hepatitis C: Peginterferon Alfa-2a Plus Ribavirin Versus Peginterferon Alfa-2b Plus Ribavirin. *Am J Health Syst Pharm*. 2009 Dec, 66(24): 2171-8.
93. **Brixner DI**, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R. (2009) Six-Month A1C, Weight and Cardiovascular Outcomes in Patients with Type 2 Diabetes Treated with Exenatide in an Ambulatory Care Setting. *Diabetes, Obesity and Metabolism*. 2009 Dec, (12): 1122-30.
94. Said Q, Marx CM, Schwartz JS, Ben-Joseph R, **Brixner DI**. (2009) Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More. *Value Health*. 2009 Oct, V13(2): P265-272.

95. McAdam-Marx C, **Brixner DI**, Metraux S, Moelter S, Field R. (2009) Antidiabetic Treatment and A1C Testing in Youth with Type 2 Diabetes in an Ambulatory Care Setting. *Diabetes*. 58(S1): A514.
96. McAdam-Marx C, Bouchard J, Aagren M, Nelson R, **Brixner DI**. (2009) Analysis of Glycaemic Control and Weight Change in Patients Initiated with Human or Analog Insulin in an US Ambulatory Care Setting. *Diabetes, Obesity and Metabolism*. 2009 Sep, 12(1): 54-63.
97. McAdam-Marx C, Ye X, Sung JC, **Brixner DI**, Kahler KH. (2009) Results of a Retrospective, Observational Pilot Study Using Electronic Medical Records to Assess the Prevalence and Characteristics of Patients with Resistant Hypertension in an Ambulatory Care Setting. *Clin Ther*. 2009 May, 31(5): 1116-23.
98. Smith MD, Drummond M, **Brixner DI**. (2009) Moving the QALY Forward: Rationale for Change. *Value Health*. 2009 Mar, 12 Suppl 1:S1-4.
99. Kane SV, Accortt NA, Magowan S, **Brixner DI**. (2009) Predictors of Persistence with 5-Aminosalicylic Acid Therapy for Ulcerative Colitis. *Aliment Pharmacol Ther*. 2009 Apr, 29(8): 855-62.
100. **Brixner DI**, Holtorf AP, Neumann PJ, Malone DC, Watkins JB. (2009) Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care. *J Manag Care Pharm*. 2009 Apr, 15(3): 275-83.
101. Drummond M, **Brixner DI**, Gold M, Kind P, McGuire A, Nord E. (2009) Toward a Consensus on the QALY. *Value in Health*. 2009 Mar-Apr, 12(s1): S31-S35.

## 2008

102. **Brixner DI**, McAdam-Marx C. (2008) Cost-Effectiveness of Insulin Analogs. *The American Journal of Managed Care*. 2008 Nov, 14(11): 766-75.
103. **Brixner DI**, Ghate SR, McAdam-Marx C, Ben-Joseph R, Said Q. (2008) Association Between Cardiometabolic Risk Factors and Body Mass Index on *Diagnosis and Treatment Codes* in an Electronic Medical Record Database. *J Manag Care Pharm*. 2008 Oct, 14(8): 756-67. **(Nominated as 1 of 15 articles by JMCP Editorial Advisory Board for 2008 JMCP Award of Excellence).**
104. **Brixner DI**, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. (2008) Assessment of Adherence, Persistence, and Costs Among Valsartan and Hydrochlorothiazide Retrospective Cohorts in Free-and Fixed-Dose Combinations. *Curr Med Res Opin*. 2008 Sep, 24(9): 2597-607.
105. Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, **Brixner DI**. (2008) Adherence with Multiple-Combination Antihypertensive Pharmacotherapies in a US Managed Care Database. *Clin Ther*. 2008 Aug, 30(8): 1558-63.
106. Hendlish SK, Horowicz-Mehler NC, **Brixner DI**, Stern LS, Doyle JJ, Chang J, Hagan M. (2008) Contraceptive and Noncontraceptive Benefits of the LNG-IUS in a Vertically Integrated HMO. *Contraception*. 2008 Jul, 78(1): 36-41. Epub 2008 May 14.
107. LaFleur J, Fish L, **Brixner, DI**. Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design. *Am Health Drug Benefits*. 2008 May; 1(4): 29-34.
108. Asche C, Said Q, Joish V, Hall CO, **Brixner DI**. (2008) Assessment of COPD-Related Outcomes Via a National Electronic Medical Record Database. *International Journal of COPD*. 2008 Jun, 3(2): 323-6.
109. Holtorf AP, Watkins JB, Mullins CD, **Brixner DI**. (2008) Incorporating Observational Data into the Formulary Decision-Making Process – Summary of a Roundtable Discussion. *J Manag Care Pharm*. 2008 Apr; 14(3): 302-8.
110. Murphy PA, **Brixner DI**. (2008) Hormonal Contraceptive Discontinuation Patterns According to Formulation: Investigation of Associations in an Administrative Claims Database. *Contraception*. 2008 Apr, 77(4): 257-63.
111. Hassanein T, Ye X, Chu TC, **Brixner DI**. (2008) Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. *Gastroenterology*. 2008 Apr, 134(4), Supplement 1: A-833.
112. Hassanein T, Ye X, Blumentals WA, **Brixner DI**. (2008) Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. *Journal of Hepatology*. 2008, 48 Supplement 2: S295-6.

113. Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, **Brixner DI**. (2008) Somnolence Effects of Antipsychotic Medications and the Risk of Unintentional Injury. *Pharmacoepidemiol Drug Saf*. 2008 Apr, 17(4): 354-64.
114. LaFleur J, McAdam-Marx C, Kirkness C, **Brixner DI**. (2008) Clinical Risk Factors for Fracture in Post-Menopausal Osteoporotic Women: a Review of the Recent Literature. *Ann Pharmacother*. 2008 Mar, 42(3): 375-86.
115. Muszbek N, **Brixner DI**, Benedict A, Keskinaslan A, Khan ZM. (2008) The Economic Consequences of Noncompliance in Cardiovascular Disease and Related Conditions: A Literature Review. *Int J Clin Pract*. 2008 Feb, 62(2): 338-51.
116. Kane SV, **Brixner DI**, Rubin DT, Sewitch MJ. (2008) The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis. *J Manag Care Pharm*. 2008 Jan, 14(1 Suppl A):s2-12; quiz s13-5.

## 2007

117. **Brixner DI**, Lenhart G, Young DC, Samuelson WM. (2007) The Effect of Fixed Combination Fluticasone and Salmeterol on Asthma Drug Utilization, Asthma Drug Cost, and Episodes of Asthma Exacerbations. *Current Medical Research and Opinion*. 2007 Nov, 23(11): 2887-95.
118. Nickman NA, Biskupiak J, Creekmore F, Shah H, **Brixner DI**. (2007) Antiplatelet Medication Management in Patients Hospitalized with Ischemic Stroke. *Am J Health Syst Pharm*. 2007 Nov, 64(21): 2250-6.
119. **Brixner DI**, Joish V, Oderda GM, Avey S, Hanson D, Cannon HE. (2007) Effects of Benefit Change Across 5 Disease States. *The American Journal of Managed Care*. 2007 Jun, 3(1): 370-6.
120. Jackson K, Nahoopii R, Said Q, Dirani R, **Brixner DI**. (2007) An Employer-Based Cost Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation. *Journal of Occupational and Environmental Medicine*. 2007 Apr, 49(4): 453-60.
121. **Brixner DI**, Said Q, Kirkness C, Oberg B, Ben-Joseph R, Oderda G. (2007) Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. *Value Health*. 2007 Jan/Feb, 10(1): S29-36.

## 2006

122. Ho MJ, Kirkness C, **Brixner DI**. (2006) Problem Based Learning in Pharmacy Management. *Journal of Pharmacy Teaching*. 2006, 13(2): 39-56.
123. Creekmore FM, Oderda GM, Pendleton RC, **Brixner DI**. (2006) Incidence and Economic Implications of Heparin-Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism. *Pharmacotherapy*. 2006 Oct, 26(10): 1438-45.
124. Joish VN, Brady E, Stockdale WA, **Brixner DI**, Dirani R. (2006) Evaluating Diagnosis and Treatment Patterns of COPD in Primary Care. *Treatments in Respiratory Medicine*. 2006 Aug, 5(4): 283-93.
125. Pichichero ME, **Brixner DI**. (2006) Rethinking the Total Cost of Care in AOM and ABS: The Impact of Improved Diagnostic Accuracy and Antibiotic Treatment Where High Efficacy and Adherence are Achievable. *American Journal of Managed Care*. 2006 Aug, 12(Suppl 10): S283-91.
126. Pichichero ME, **Brixner DI**. (2006) A Review of Recommended Antibiotic Therapies with Impact on Outcomes in Acute Otitis Media and Acute Bacterial Sinusitis. *American Journal of Managed Care*. 2006 Aug, 12(Suppl 10): S292-302.
127. LaFleur J, Thompson C, Joish VN, Charland S, Oderda GM, **Brixner DI**. (2006) Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended Release Niacin. *Ann Pharmacother*. 2006 Jul-Aug, 40(7): 1274-79.
128. **Brixner DI**. (2006) Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real-World Setting. *Am J Managed Care*, 12(Suppl 7): S191-8; Erratum in: *Am J Manag Care*. 2006 July, 12(7): 370.
129. **Brixner DI**. (2006) Managing Osteoporosis in a Managed Care Population. *American Journal of Managed Care*. 2006 May, 12(7 Suppl): S199-202.
130. **Brixner DI**. (2006) The Case Against Excessive Cost-Sharing. *American Journal of Managed Care*. 2006 Apr, 12(6 Suppl): S162-64.

131. **Brixner DI**, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, Oderda GM. (2006) Naturalistic Impact of Second-Generation Antipsychotics on Weight Gain. *Ann Pharmacother*. 2006 Apr, 40(4): 626-32.
132. **Brixner DI**, Oderda GM, Nickman NA, Beveridge R, Jorgenson JA. (2006) Documentation of Chemotherapy Infusion Preparation Costs in Academic and Community-Based Oncology Practices. *Journal of the National Comprehensive Cancer Network*. 2006 Mar, 4(3): 197-208.
133. **Brixner DI**, Oderda GM, Roland CL, Rublee DA. (2006) Opioid Expenditures and Utilization in the Medicaid System. *J Pain Palliat Care Pharmacother*. 2006 Jan, 20(1): 5-13.
134. Biskupiak JE, **Brixner DI**, Howard K, Oderda GM. (2006) Gastrointestinal Complications of Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs. *J Pain Palliat Care Pharmacother*. 2006 Jan, 20(3): 7-14.

## 2005

135. Gerbino PP, **Brixner DI**, Sbarbaro J, Nicolau D. (2005) Appropriate Initial Antibiotic Therapy in the Treatment of Community-Acquired Respiratory Tract Infections. *Managed Care Interface*, 18(12): 41-8.
136. Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, Joshua-Gotlib S, **Brixner DI**. (2005) The Economic Impact of GERD and PUD: Examination of Direct and Indirect Costs Using a Large Integrated Employer Claims Database. *Curr Med Res Opin*, 21(4): 535-44.
137. Trost LF 3rd, Wender RC, Suter CC, Von Worley AM, **Brixner DI**, Rosenberg JH, Gunter MJ. (2005) Management of Epilepsy in Adults. Treatment Guidelines. *Postgrad Med*, 118(6): 29-33.
138. Trost LF 3rd, Wender RC, Suter CC, Rosenberg JH, **Brixner DI**, Von Worley AM, Gunter MJ. (2005) Management of Epilepsy in Adults. Diagnosis Guidelines. *Postgrad Med*, 118(6): 22-6.
139. Sullivan PW, Valuck R, **Brixner DI**, Armstrong EP. (2005) A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors. *Pharmacy and Therapeutics*, 30(2): 96-106.
140. **Brixner DI**, Ho MJ. (2005) Clinical, Humanistic, and Economic Outcomes of Gout. *American Journal of Managed Care*, 11(15 Suppl): S459-64.
141. **Brixner DI**. (2005) Improving Acute Otitis Media Outcomes Through Proper Antibiotic Use and Adherence. *American Journal of Managed Care*, 11(6 Suppl): S202-10.
142. **Brixner DI**. (2005) Managing the Continuum of Treatment: Modeling the Economic Impact of Treating Diabetes. *Journal of Managed Care Pharmacy*, 11: S19-S22.

## 2004

143. Briggs DD, **Brixner DI**, Cannon HE, George DL. (2004) Overview of Chronic Obstructive Pulmonary Disease: New Approaches to Patient Management in Managed Care Systems. *Journal of Managed Care Pharmacy*, 10: S2-10.
144. Joish VN, **Brixner DI**. (2004) Back Pain and Productivity: Measuring Worker Productivity From an Employer's Perspective. *Journal of Pain & Palliative Care Pharmacotherapy*, 18(2): 79-85.
145. **Brixner DI**. (2004) Clinical and Economic Outcomes in the Treatment of Lower Respiratory Tract Infections. *American Journal of Managed Care*, 10: S400-7.
146. Kane S, Borisov NN, **Brixner DI**. (2004) Pharmacoeconomic Evaluation of Gastrointestinal Tract Events During Treatment with Resedronate or Alendronate: a Retrospective Cohort Study. *American Journal of Managed Care*, 10(7): S216-26.
147. Ho MJ, Joish VN, LaFleur J, Christensen RL, **Brixner DI**. (2004) Pharmacoeconomic Analysis of Oral Triptans. *Formulary*, 39: 356-57.
148. Brandes JL, **Brixner DI**. (2004) Migraine Matters: The Role of Triptans in Relieving the Burden in Management Care. *Journal of Managed Care Pharmacy*, 10(4b): S2-12.
149. Gunter MJ, Worley AV, Carter S, Gregory C, **Brixner DI**. (2004) Impact of a Seizure Disorder Disease Management Program on Patient-Reported Quality of Life. *Disease Management*, 7(4): 333-47.

## 2002

150. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiwitz RH, **Brixner DI**, Vlasses PH. (2002) Using a Multihospital Systems Framework to Evaluate and Establish Drug Use Policy. *Journal of Medical Systems*, 24(4): 235-46.

## 1999-1990

151. Clouse J, Gagnon JP, Boyer G, **Brixner DI**, Clancy C, De Lissovoy G, Morris L, Neumann P, Robinow A, Sullivan S. (1999) Panel 5: Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making. *Value in Health*, March 2(2): 92-8.
152. Wilson M, Patwell J, Shoheiber O, Eicher J, **Brixner DI**, et-al. (1998) Clinical and Economic Implications of Drug Utilization Patterns in the Treatment of Hypertension with ACE Inhibitors and Calcium Channel Blockers in a Managed Care Setting. *Journal of Managed Care Pharmacy*, 4(1): 194-202.
153. Kuehl M, **Brixner DI**, Broom AD, Avery TL, Blakley RL. (1998) Cytotoxicity Uptake, Polyglutamate Formation, and Antileukemic Effects of 8-Deaza Analogues of Methotrexate and Aminopterin in Mice. *Cancer Research*, 48(6): 1481-88.
154. Okano GJ, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, **Brixner DI**. (1997) Patterns of Antihypertensive Use Among Patients in the US Department of Defense Database Initially Prescribed an Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker. *Clin Ther*, 19(6): 1433-45; discussion 1424-25.
155. **Brixner DI**, Bull SA. (1997) The Challenge of Integrating Monoclonal Antibodies into the Current Healthcare System. *American Journal of Managed Care*, 3(6): 903-11.
156. **Brixner DI**. (1996) Pharmacoeconomics and Outcomes Research in the Pharmaceutical Industry. *Journal of Managed Care Pharmacy*.
157. Rao TN, **Brixner DI**, Srinivasan A, Kasina S, Vanderheyden JL, Wester DW, Fritzberg AR. (1991) International Journal of Radiation Applications and Instrumentation. Part A. *Applied Radiation and Isotopes*, 42(6): 525-30.
158. **Brixner DI**. (1991) Monoclonal Antibodies: From the Research Lab to the Pharmacy. *J Pharm Practice*, 4(1): 94.
159. Rao RN, **Brixner DI**, Srinivasan A, Kasina S, Vanderheyden JL, Wester DW, Fritzberg AR. (1991) Synthesis and Characterization of Diamide Dithiol Complexes of Technetium (V) and Rhenium (V). Assignment of Stereochemistry of the Chelate Epimers by NMR Spectroscopy. *Intl J Radiation Applications and Inst*, 42(6): 525-530.

## 1989-1980

160. Bayomi SM, **Brixner DI**, Eissa HM, Broom AD. (1988) An N10-Propargylated Derivative of a Multisubstrate Inhibitor of Thymidylate Synthetase. *Nucleosides and Nucleotides*, 7(1): 103-115.
161. **Brixner DI**, Ueda T, Cheng YC, Hynes JB, Broom AD. (1987) Folate Analogues as Inhibitors of Thymidylate Synthase. *J Med Chem*, 30(4): 675-78.
162. Beres J, Lee Y, **Brixner DI**, Olsen JJ, Schweizer MP. (1986) Alkaline Degradation of 1, 3-Di-(2-hydroxyethyl) Adensine 3', 5'-Cyclic Phosphate. *Nucleosides and Nucleotides*, 5(1): 1-13.

## B. Other Publications

1. Stenehjem D, Udomaksorn S, Cheng Y, Pflieger L, Au T, Buys S, **Brixner D**. Evaluation of the Relevance and Access of HER-Based Variables to Support Personalized Medicine in Breast Cancer. *Cogent Medicine*, Vol 3, Oct 2016, Issue 1.
2. **Brixner D**, Egami M, Garrison L, Jönsson, Neumann P, Kamae I. Regenerative Medicine and Health Technology Assessment: Vision and Challenges. *JJ Regener Med*. Aug 2016, 1(3): 014.
3. **Brixner DI**. (2012) Commentary: AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. *J Manage Care Pharm*, 2012 Jan-Feb 18(1Suppl A) 1-22.
4. **Brixner DI**. (2012) Commentary: Payer Perspective in Evaluating Diabetic Medications for Glycemic Control in Type 2 Diabetes. *Supplemental of Journal of Managed Care Pharmacy*, Jan/Feb 18(1a):S15.
5. **Brixner DI**. (2011) Clinical Commentary 2: The Payer Perspective on ACEIs, ARBs, and DRIs for Treating Essential Hypertension. *Supplemental of Journal of Managed Care Pharmacy*, October 17(8): S9.
6. **Brixner DI**. (2011) Commentary: The Payer Perspective on Evaluating Add-On Therapy to Standard Medical Therapy in Managing Stable Ischemic Heart Disease *Supplement to Journal of Managed Care Pharmacy*. June 17(5):S9, J.



7. **Brixner DI.** (2011) Acknowledgement from Qayyum R, Green L. AHRQ's Comparative Effectiveness Research on Premixed Insulin Analogues for Adults with Type 2 Diabetes: Understanding and Applying the Systematic Review Findings. *Supplement to Journal of Managed Care Pharmacy*, 17(3): S1-S19.
8. **Brixner DI.** (2011) Clinical Reflection: Patient Access to Insulin and Noninsulin Diabetes Therapies. *Supplemental to Journal of Managed Care Pharmacy*, 17(3): S13, April 2011.
9. Hassanein T, Xin Y, Blumentals WA, Prabhakar A, **Brixner DI.** (2010) Treatment Rates and Clinical Outcomes in Patients with Hepatitis C: Results from a US-Based Health Plan Analysis. [*Letter to the Editor*] April 2010.
10. **Brixner DI.** (2008) Comparative Effectiveness: What Are We Comparing? *ISPOR Connections*, [President's Message] March 2008.
11. **Brixner DI.** (2008) Translational Research and the Value Equation. *ISPOR Connections*, [President's Message] January 2008.
12. **Brixner DI.** (2007) Reflections on the Quality of the QALY. *ISPOR Connections* [President's Message] December 2007.
13. **Brixner DI.** (2007) Prevalence and burden of migraine and the impact on managed care. Currents: Pain Management News and Research, *E-Newsletter of the American Academy of Pain Management*, Nov. 2007 16(7).
14. **Brixner DI.** (2007) Prescription Drug Spending Around the World: Does Anyone Have it Right? *ISPOR Connections*, [President's Message] October 2007.
15. **Brixner DI,** Miller P, Fox J, Calabrese D, Tangalos E, Gruber J, Skinner N. (2007) The Role of Observational Data in Clinical Decision-Making for Osteoporosis: Commentaries from Managed Care and Senior Care [C.E. Program] *Hotwire for Managed Markets*, March 2007.
16. **Brixner DI.** (2007) Prevalence and Burden of Migraine and the Impact on Managed Care. *Manag Care*, 16(7 Suppl 7): 2-3; discussion 15-7.
17. LaFleur J, Thompson C, Ho M, Stockdale W, Charland SL, Oderda G, **Brixner DI.** (2005) Cost Analysis of Combination vs. Single Dosage Lipid Lowering. *Hospital Formulary*, 40(7): 233-34.
18. Asche CV, **Brixner DI,** Oderda GM. (2005) Has the Cost-Effectiveness of Xolair (Omalizumab) Been Underestimated? [Letter] *J Allergy Clin Immunol*, 115(5): 1095; author reply 1095-6.
19. **Brixner DI.** (2004) Standardizing Managed Care Formulary Submissions: the AMCP Format. *Managed Care*, 13(5): 14-17.
20. **Brixner DI,** Dugowson CE. (1994) Utilization Evaluation of NSAIDS in a Managed Care Setting: A Case Study. *Medical Interface*, 7(11): 145-50.
21. **Brixner DI.** (1991) Biotechnology: Impact on Pharmacists. *Pharmacy Times*, 39.
22. **Brixner DI.** (1987) Inhibitors of Thymidylate Synthetase: A Mechanistic Probe. *Thesis Dissertation*.

## **VII. Books and Book Chapters**

1. Hu S, Holtorf A, Wijaya K, He J, **Brixner D.** (2019) Value-Based Evaluation of Chinese Provincial Health Insurance Policy Schemes. Published online. *IntechOpen*.
2. Vailancourt A, Chisholm Burns M, **Brixner, DI.** (2012) Creating and Identifying Desirable Workplaces. "Pharmacy Leadership, Marketing and Finance 2<sup>nd</sup> edition." Chapter 23, (Marie A. Chisholm-Burns) *Jones and Bartlett Learning*. p. 400-415.
3. Holtorf A, Rinde H, Rupprecht F, Alder H, **Brixner DI.** (2012) The Economic Impact of Bariatric Surgery in "Advanced Bariatric and Metabolic Surgery" (Chih-Kun Huang). Croatia, *Intech*. p. 61-86.
4. **Brixner DI,** Joish VN, Biskupiak JE, Shah H. (2008) Pharmacoeconomic Research in Managed Care in "Managed Care and Pharmacoeconomics" (Robert Navarro). 2<sup>nd</sup> edition, New York, *Jones and Bartlett Publishers*.
5. **Brixner DI,** Szeinbach S, Shah H, Mehta S, Ryu S. (1999) Pharmacoeconomic Research in Managed Care in "Managed Care and Pharmacoeconomics" (Navarro R). New York, *Aspen Publishers*.
6. **Brixner DI,** Pochtar P, Talbott JE. (1997) Pharmacoeconomics in Making Sense of Managed Care Volume II: Strategic Positioning" (Miller KA, Miller EK). San Francisco, CA, *Jossey-Bass Publishers*.

7. **Brixner DI.** (1993) *Biotechnology Products: An Overview in “Biotechnology and Pharmacy”* (John M. Pezzuto, Michael E. Johnson, Henri R. Manasse). New York, *Chapman and Hall Publishers*.

## **VIII. Posters/Abstracts**

### **2019**

1. Elliott SW, Long C, Mydlarz D, **Brixner D**, Megibben J, Simmons J. Impact of Adherence to 2013 American College of Cardiology (ACC) and the American Health Association (AHA) Statin Guidelines Post-Revascularization on Cardiovascular Outcomes. [Poster] American College of Cardiology’s 68<sup>th</sup> Annual Scientific Session, New Orleans, LA. March 16-18, 2019.

### **2018**

2. Tan M, Kim K, Olsen C, **Brixner D**. Effect of Medication Adherence on Glycemic Control in Patients with Type 2 Diabetes. [Poster] ASHP Midyear 2018 Clinical Meeting and Exhibition, Anaheim, CA. December 2-6, 2018.
3. Connor Willis, Jyothi Menon, Sudhir Unni, Trang Au, Briana Ndife, George J Joseph, Gaetano J Bonifacio, Eytan M. Stein, Srinivas K. Tantravahi, Paul J Shami, Tibor Kovacsovics, **Diana Brixner**, David Dean Stenehjelm. Emerging Real-World Midostaurin Treatment Patterns and Outcomes in FLT3-Mutated Acute Myeloid Leukemia at a Comprehensive Cancer Center. [Poster] 60<sup>th</sup> ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018.
4. Trang H. Au, Hillevi Bauer, Jyothi Menon, Connor Willis, Eli Iacob, Junjie Ma, Alexandre Watanabe, Ryan Nelson, Beata Korytowsky, Prianka Singh, Alexander Marshall, Nicole Willmarth, Phioanh Leia Nghiemphu, Laura Dovek, Katherine B. Peters, Bea Balajonda, Adam Louis Cohen, Howard Colman, David D. Stenehjelm, **Diana I. Brixner**. Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S. [Poster] ASCO 2018 Palliative and Supportive Care in Oncology Symposium, San Diego, CA, November 16-17, 2018.
5. Kenny J, Freitag A, Mountian I, Szegvari B, **Brixner D**, Maniadakis N. How Frequently is Patient Experience Formally Assessed in Health Technology Assessments? Results from a Systematic Literature Review. [Poster] ISPOR Europe 2018, Barcelona, Spain. November 10-14, 2018.
6. **Diana Brixner**, Eric Faulkner, Anke-Peggy Holtorf, Maarten J. Ijzerman. Towards a Value Framework for Precision Medicine: Recommendations from the ISPOR Precision Medicine Special Interest Group. [Forum Presentation] ISPOR Europe 2018, Barcelona, Spain, November 10-14, 2018.
7. Connor Willis, Michelle Fiander, Dao Tran, Beata korytowsky, John-Michael Thomas, Signe Fransen, Florencio Calderon, Teresa Zyczynski, Lisa Siegartel, **Diana Brixner**, David Stenehjelm. A Systematic Literature Review (SLR) of Tumor Mutational Burden (TMB) and Efficacy with immunotherapy (IO) in Lung Cancer. [Poster] SITC 2018, Washington, DC, November 7-11, 2018.
8. Connor Willis, Lionel Pinto, Michael Faithe, Sudhir Unni, Matthew Rim, Jeff Dunn, Reema Patel, **Diana Brixner**, Joseph Biskupiak. Prior Authorization (PA) Approval Rates for Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in the US Intermountain West. [Poster] AMCP Nexus 2018, Orlando, FL, October 22-25, 2018.
9. Malinda S. Tan, Kibum Kim, Cody Olsen, **Diana Brixner**. The Effect of Treatment Intensification on Glycemic Control in Patients with Type 2 Diabetes. [Poster] AMCP Nexus 2018, Orlando, FL, October 22-25, 2018.
10. **Brixner D**, Woodward TC, Seifter N, Biskupiak J, Marciniak M, Neumann P, Oderda G. Preapproval Information Exchange (PIE): Perspectives from U.S. Population Health Decision Makers on Preferences for Early Engagement on Investigational Therapies. [Poster] AMCP Nexus 2018, Orlando, FL, October 22-25, 2018.
11. Joseph E. Biskupiak, Tina Lin, Robert Kang, April Armstrong, **Diana I. Brixner**. Comparative Efficacy of Fixed Combination Halobetasol/Tazarotene Lotion to Apremilast for Treatment of Moderately Severe Plaque Psoriasis Using the Investigator Global Assessment and Body Surface Area to Assess Disease Severity Product (IGAxBSA). [Poster] AMCP Nexus 2018, Orlando, FL. October 22-25, 2018.
12. Eman Biltaji, Joseph Biskupiak, Catherine M.T. Sherwin, Gwendolyn A. McMillin, **Diana Brixner**. Optimizing the Value of Pharmacogenetic Risk Screening Among Patients with Polypharmacy: A Healthcare System Experience. [Poster] American Society of Human Genetics Symposium, San Diego, CA. October 16-20, 2018.

13. Surachat Ngorsuraches, Natasha Frost, Jerome Freeman, **Diana Brixner**, Jane Mort, James Clem. Patients' Preferences and Willingness-to-Pay for Disease-Modifying Therapies: A Discrete Choice Experiment in the U.S. [Poster] 2018 Annual Meeting of the Consortium of Multiple Sclerosis Centers, Nashville, TN. May 30-June 2, 2018.
14. Jyothi Menon, Connor Willis, Sudhir Unni, Trang Au, Briana Ndife, George Joseph, **Diana Brixner**, Eytan Stein, Srinivas Tantravahi, Paul Shami, Tibor Kovacsovics, David Stenehjem. FLT3 Mutated and Wildtype Acute Myeloid Leukemia Treatment Patterns and Outcomes at a Comprehensive Cancer Center. [Poster] ISPOR 2018, Baltimore, MD, May 19-23, 2018.
15. **Diana Brixner**, David T. Rubin, Philip Mease, Manish Mittal, Harry Liu, Matthew David, Arijit Ganguli, A. Mark Fendrick. Benefits of a Patient Support Program on Adherence, Discontinuation, and Costs in the US Commercial Population of Adalimumab-Treated Patients. [Poster] AMCP Managed Care and Specialty Pharmacy Annual Meeting 2018, Boston, MA. April 23-26, 2018.
16. Eman Biltaji, Joseph Biskupiak, Catherine M.T. Sherwin, Gwendolyn A. McMillin, **Diana Brixner**. Optimizing the Value of Pharmacogenetic Risk Screening Among Patients with Polypharmacy: A Healthcare System Experience. [Poster] AMCP Annual Meeting 2018, Boston, MA, April 23-26, 2018.
17. Kibum Kim, Sudhir Unni, Carrie McAdam-Marx, Sheila M. Thomas, Cody Olsen, Bryan Johnstone, Matt Mitchell, **Diana Brixner**. Treatment Intensification Patterns and Glycemic Control Outcomes in Patients with Under-controlled Type 2 Diabetes after Two Oral Antidiabetic Agents. [Poster] AMCP Annual Meeting 2018, Boston, MA, April 23-26, 2018.
18. Ram Gouripeddi, Rishi Deka, Thomas Reese, Ryan Butcher, Bradley Martin, Jeff Talbert, Bernie LaSalle, Julio Facelli, **Diana Brixner**. Reproducibility of Electronic Health Record Research Data Requests. [Poster] Translational Science 2018, Washington, DC. April 19-21, 2018.
19. Grant Lawless, Sam Nussbaum, **Diana Brixner**. Advancing Precision Medicine in Rheumatoid Arthritis: The Impact of Biomarkers on Outcomes and Cost. [Poster] DIA Europe 2018, Basel, Switzerland. April 17-19, 2018.
20. Eman Biltaji, Joseph Biskupiak, Catherine M.T. Sherwin, Gwendolyn A. McMillin, **Diana Brixner**. Optimizing the Value of Pharmacogenetics Risk Screening Among Patients with Polypharmacy: A Healthcare System Experience. [Poster] 13<sup>th</sup> Annual Utah Health Services Research Conference: Partnering For Better Health by Doing What Works. University of Utah, Salt Lake City, UT. March 22, 2018.

## 2017

21. Trang Au, Hillevi Bauer, Junjie Ma, Ryan Nelson, Alexandre Watanabe, Prianka Singh, Beata KorytowskyBarbara, Elizabeth Wilson, Nicole Willmarth, Adam Cohen, Howard Colman, David Stenehjem, **Diana Brixner**. Development of a Novel Burden Survey for Caregivers of Glioblastoma Multiforme Patients. [Poster] 22<sup>nd</sup> Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. San Francisco, CA, November 16-19, 2017.
22. Mistry R, Suri G, Young KC, Hettle R, May JR, **Brixner D**, Oderda G, Biskupiak J, tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal A. Budget Impact of Ribociclib Plus Letrozole for the Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HERS-) Advanced or Metastatic Breast Cancer from a US Private Third-Party Payer Perspective. [Poster] ISPOR 20<sup>th</sup> Annual European Congress, Glasgow, Scotland, November 4-8, 2017.
23. Suri G, Mistry R, Young KC, Hettle R, May JR, **Brixner D**, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal A. Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for the Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Meta Static Breast Cancer from a US Private Third-Party Payer Perspective. [Poster] ISPOR 20<sup>th</sup> Annual European Congress, Glasgow, Scotland, November 4-8, 2017.
24. Biskupiak J, Yoo M, Kim J, Bauer H, Messali A, Ng-Mak D, Rajagopalan K, **Brixner D**. Impact of Medication Changes During Hospital Stay on Postdischarge Hospital Readmissions and Health Care Charges: Analysis of Outcomes Among Adults with Schizophrenia or Bipolar Disorder Admitted to an Academic Neuropsychiatric Hospital. [Poster] Academy of Managed Care Pharmacy Nexus 2017, Dallas, Texas, October 16-19, 2017.

25. Ma J, Xuan S, Lawson B O, **Brixner D**. A Systematic Review of Questionnaires Used to Evaluate Caregiver Burden in Patients with Primary Malignant Brain Tumors. [Poster] Western Pharmacoeconomics and Outcomes Research Conference, Albuquerque, NM, October 4-6, 2017.
26. Biltaji E, Au T, Walker B, Ose J, Ulrich CM, Stenehjem D, **Brixner D**. Cost Threshold Analysis of Genotype-Guided Aspirin Use for Colorectal Cancer Prevention. [Poster] ISPOR 22<sup>nd</sup> Annual International Meeting, Boston, MA. May 20-24, 2017.
27. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, **Brixner DI**, Schiffman JD. Cost-Effectiveness Analysis of Early Cancer Surveillance for Patients with Li-Fraumeni Syndrome. [Poster] ISPOR 22<sup>nd</sup> Annual International Meeting, Boston, MA. May 20-24, 2017.
28. Jiao T, Zhang Y, Liou T, Stevens V, Young D, **Brixner D**. The Optimal Treatment Regime to Delay the Onset of Mucoid Pseudomonas Aeruginosa Pulmonary Infection on Pediatric Cystic Fibrosis Patients. [Podium Presentation] ISPOR 22<sup>nd</sup> Annual International Meeting, Boston, MA. May 20-24, 2017.
29. Biskupiak J, Tak C, Yoo M, **Brixner D**, Tomazos I, L'Italien G, Donato B, Denker A. Predictors of Fracture Risk in Probable Hypophosphatasia Patients Identified Within an Electronic Health Record Database. [Poster] ENDO 2017, Orlando FL, April 1-4, 2017.
30. Biskupiak J, Tak C, Yoo M, **Brixner D**, Tomazos I, L'Italien G, Donato B, Denker A. Fracture Burden in Probable Hypophosphatasia Patients Identified Within an Electronic Health Record Database. [Poster] ENDO 2017, Orlando FL, April 1-4, 2017.

## 2016

31. Stenehjem D, Au T, Ngorsuraches S, Bauer H, Ma J, Pfeiffer C, Stanford A, Schwartz J, Shah M, Okoro T, Korytowsky B, Oderda G, **Brixner D**. Patient and Provider Relations and Perceptions Regarding Melanoma Treatment Decisions. [Poster] Society for Melanoma Research Congress, Boston, MA, November 6-9, 2016.
32. Boklage S, Bellows B, Sainski-Nguyen A, Olsen C, Charland S, **Brixner D**, Mitchell M. A Comparison of Statin Intolerance Classification Algorithms for Newly Prescribed Statin Patients [Poster] AMCP Nexus 2016, National Harbor, Washington D.C., Oct 3-6 2016]
33. Bellows B, Olsen C, Sainski-Nguyen A, Boklage S, Charland S, Mitchell M, **Brixner D**. Evaluation of the Practical Utility of Statin Intolerance Definitions as Recommended by a Regional Managed Care and Clinical Expert Panel [Poster] AMCP Nexus 2016, National Harbor, Washington D.C., Oct 3-6 2016
34. Stenehjem D, Au T, Ngorsuraches S, Bauer H, Okoro T, Wanishayakorn T, Korytowsky B, Odera G, **Brixner D**. Patient and Provider Preferences for Melanoma Treatment: A Discrete Choice Experiment and Willingness-To-Pay Estimates for Immunotherapy and BRAF/MEK Inhibition. [Poster] AMCP Nexus 2016, National Harbor, Washington D.C., Oct 3-6 2016
35. Biskupiak J, Sainski A, Yoo M, **Brixner D**. Utilization of an Algorithm to Identify Individuals at Risk for Hypophosphatasia (HPP) Within an Electronic Health Record (EHR) Database. [Poster] ASBMR, Atlanta Georgia, Sept. 16-19, 2016.
36. **Brixner D**, Manladakis N, Kalo Z, Hu S, Johnston A, Shen J, Wijaya KE. Application of Multi-Criteria Decision Analysis (MCDA) Scoring as an HTA Methodology for Off-Patent Pharmaceuticals (OPP) in Emerging Markets. [Poster] ISPOR 7<sup>th</sup> Asia-Pacific Conference, Singapore, Sept 3-6, 2016.
37. Biltaji E, Bellows B, Stenehjem D, **Brixner D**. Validation of a Cost-effectiveness Model Comparing Accuracy of Genetic Tests for BRCA Mutations. [Poster] ISPOR 21<sup>st</sup> Annual International Meeting, Washington, DC. May 21-25, 2016.
38. Biltaji E, Stenehjem D, Schiffman J, **Brixner D**. Predictors of NGS Testing in Metastatic Colorectal Cancer (mCRC). [Poster] ISPOR 21<sup>st</sup> Annual International Meeting, Washington, DC. May 21-25, 2016.
39. Jiao T, Biskupiak J, Ye X, Unni S, Dowd C, Fink A, Feng L, Erdo J, **Brixner D**. Development of a Linked Database for Cystic Fibrosis Research by Integrating a Patient Registry with an Administrative Claims Database. [Poster] ISPOR 21<sup>st</sup> Annual International Meeting, Washington, DC. May 21-25, 2016.
40. Biskupiak JE, Unni S, Jiao T, Ye X, Dowd C, Fink A, Feng L, Erdo J, **Brixner D**. Evaluation of a Linked Database for Cystic Fibrosis Research on Clinical, Demographic and Resource Use Variables. [Poster] AMCP 28<sup>th</sup> Annual Meeting & Expo, San Francisco, CA. April 19-22, 2016.

41. Bellows B, Olsen C, Sainski-Nguyen A, Boklage S, Charland S, Plauschinat C, Mitchell M, **Brixner D**. Drivers of Statin Intolerance in Claims Data as Defined by a Regional Managed Care and Clinical Expert Panel. [Poster] AMCP 28<sup>th</sup> Annual Meeting & Expo, San Francisco, CA. April 19-22, 2016.

## 2015

42. Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, **Brixner D**. Value Assessment for Genetic Testing of Drug Variation in an Elderly Population. [Poster] ISPOR 18<sup>th</sup> Annual European Congress, Milan, Italy. November 7-11, 2015.
43. Rochau U, Vukicevic D, Schmidt S, Stenehjem D, **Brixner D**, Radich J, Gastl G, Siebert U. Cost-Effectiveness Analysis on Starting Patients with Chronic Myeloid Leukemia on a Highly Potent Tyrosine Kinase Inhibitor and Early Switching to Imatinib. [Poster] ISPOR 18<sup>th</sup> Annual European Congress, Milan, Italy. November 7-11, 2015.
44. Stenehjem D, Korytowsky B, Oderda G, Wanishayakorn T, Bauer H, **Brixner D**. Understanding the Impact of Patient and Physician Preferences in Personalized Treatment for Melanoma Using A Discrete Choice Experiment. [Poster] ISPOR 18<sup>th</sup> Annual European Congress, Milan, Italy. November 7-11, 2015.
45. Biskupiak J, Biltaji E, Bress A, Ye X, Unni S, Newman R, Ashcraft K, Mamiya T, **Brixner D**. Cost Consequence Analysis for Pharmacogenetic Testing in an Elderly Population. [Poster] AMCP 2015 Nexus, Orlando, Florida. October 26-29, 2015.
46. Biltaji E, **Brixner D**, McAdam-Marx C, Sweeney C, Gligorich K, Bronner M, Sharma S, Schiffman J D, Stenehjem D. Characterization of NGS Testing at Huntsman Cancer Institute. [Poster] Huntsman Cancer Institute Translating Cancer Epidemiology from Cells to Clinic and Population, Salt Lake City, Utah. October 23-25, 2015.
47. Biltaji E, **Brixner D**, McAdam-Marx C, Sweeney C, Gligorich K, Bronner M, Sharma S, Schiffman J.D., Stenehjem D. Demographics and Tumor Characteristics of Patients Undergoing Genomic Profiling. [Poster] Huntsman Cancer Institute Translating Cancer Epidemiology from Cells to Clinic and Population, Salt Lake City, Utah. October 23-25, 2015.
48. Mamiya T, Biltaji E, Ashcraft K, Thirumaran R, Sass R, **Brixner D**. Provider Acceptance Rates and Perceived Usefulness of Pharmacogenetic Recommendations Provided by a Pharmacist and clinical Decision Support Tool. [Poster] 2015 ACCP Global Conference on Clinical Pharmacy, San Francisco, CA. October 17-21, 2015.
49. Rochau U, Vukicevic D, Schmidt S, Stenehjem D, **Brixner D**, Radich J, Gastl G, Siebert U. Chronic Myeloid Leukemia Treatment: Starting with a highly Potent Tyrosine Kinase Inhibitor and Early Switching to Imatinib? [Poster] SMDM 37<sup>th</sup> Annual North American Meeting, St. Louis, MO. October 18-21, 2015.
50. Schnell-Inderst P, Hunger T, Luzak A, Mayer A, Buhn S, Jahn B, Rochau U, **Brixner D**, Garrison L, Krahn M, Payne K, Clifford T, Steyerberg E, Mortensen GL, Hebborn A, Pugner K, Dietz B, Endel G, Siebert U. Results of an International Expert Task Force on a Health Technology Assessment Framework for Personalized Medicine in Cancer. [Poster] Health Technology Assessment international 12<sup>th</sup> Annual Meeting, Oslo, Norway. June 15-17, 2015.
51. Kuo K, **Brixner D**, Lipman A, Hung M, Oderda G. Characteristics Of Combination Pharmacotherapy In Patients With Diabetic Painful Neuropathy (Dpn). [Poster] ISPOR 20th Annual International Meeting. Philadelphia, Pennsylvania. May 16-20, 2015.
52. Ma J, Xuan S, Tak C, **Brixner D**. Meta-Analysis Of The Safety Of Sipuleucel-T Immunotherapy In Prostate Cancer. [Poster] ISPOR 20th Annual International Meeting. Philadelphia, Pennsylvania. May 16-20, 2015.
53. Bress A, Unni S, Biltaji E, Sass RS, Mamiya T, Ye X, Yu B, Biskupiak JE, **Brixner D**. Evaluation Of The Potential Impact Of Drug-Gene Interaction Risk (DGIR) On Health Resource Utilization (HRU). [Poster] ISPOR 20th Annual International Meeting. Philadelphia, Pennsylvania. May 16-20, 2015.
54. **Brixner D**, Meltzer EO, Morland K, Carroll CA, Lipworth BJ. The Importance Of Anchor Based Minimal Clinically Important Difference (MCID) To Health Technology Assessment Of Established Intranasal Allergic Rhinitis Treatments. [Poster] ISPOR 20th Annual International Meeting. Philadelphia, Pennsylvania. May 16-20, 2015.
55. Bress A, King J, Singhal M, **Brixner D**, Kielhorn A, Patel H, Maya J, Biskupiak JE, Munger M. Outcomes And Health Resource Utilization Among Patients With Heart Failure With Reduced Ejection Fraction

(HFREF) At An Academic Medical Center (AMC) In The United States. [Podium Presentation] ISPOR 20th Annual International Meeting. Philadelphia, Pennsylvania. May 16-20, 2015.

56. Bress A, Biltaji E, Ye X, Mamiya T, Biskupiak J, **Brixner D**. Characterization of an Elderly Population with Potential for Drug-Gene Interactions to Determine the Value of Pharmacogenetic Risk Screening. AMCP's 27<sup>th</sup> Annual Meeting & Expo. San Diego, California. April 7-10, 2015.
57. Burgoyne DS, **Brixner D**, Kansal A, Paramore C, Chitnis A, Bell JA, Holly P, Ben-Joseph R. Extended-Release Opioid Treatment Patterns Following Initiation of Immediate-Release Hydrocodone. AMCP's 27th Annual Meeting & Expo. San Diego, California. April 7-10, 2015.
58. Palmer K, Nickman N, Moorman K, Owen D, **Brixner D**, Jennings BT. Using Failure Mode and Effects Analysis (FMEA) Methods to Identify Barriers Contributing to Low Human Papillomavirus (HPV) Vaccination Rates in a University-Based Community Health Clinic. [Poster] APhA Annual Meeting and Exposition. San Diego, California. March 27-30, 2015.
59. King J, Bress A, Singhal M, **Brixner D**, Biskupiak J. Outcomes and health resource utilization among patients with heart failure with reduced ejection fraction (HFREF) at an academic medical center (AMC) in the United States. [Poster] Western Pharmacoeconomics Conference. Denver, Colorado. March 5-6, 2015.
60. Sainski A, **Brixner D**. Outcomes Research on Regenerative Medicine in the United States. [Poster] Western Pharmacoeconomics Conference. Denver, Colorado. March 5-6, 2015.

## 2014

61. Stenhjem D, Rochau U, **Brixner D**, Oderda G, Kuo K, Kluibenschädl M, Siebert U. Decision Analysis On The Cost-Effectiveness Of Sequential Treatment Strategies For Patients With Chronic Myeloid Leukemia In The United States. [Poster] ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 8-12, 2014.
62. **Brixner D**, Holtorf A, Palacios D. The Role Of Patients In Clinical Research And Evidence Based Decision Making As Reported Via A Survey Of Patient Advocates. [Poster] ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 8-12, 2014.
63. **Brixner D**, Holtorf A, Palacios D. Are Patient Reported Outcomes Relevant To Patients? Learnings From A Patient Advocate Survey. [Poster] ISPOR 17th Annual European Congress. Amsterdam, The Netherlands. November 8-12, 2014.
64. Stenhjem D, Rochau U, **Brixner D**, Oderda G, Kuo K, Kluibenschädl M, Siebert U. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia ThPatients in the United States. [Poster] 36th Annual Meeting of the Society for Medical Decision Making. Miami, Florida. October 18-22, 2014.
65. Stenhjem DD, Bellows BK, Kaldate R, Jones JT, Yager K, Siebert U, **Brixner DI**. Cost-Utility Analysis of a Prognostic Test for early stage non-small cell lung cancer (NSCLC) [Poster] AMCP 2014 Nexus Meeting. Boston, MA. October 7-10, 2014.
66. Unni S, Schauerhamer M, Deka R, Tyczynski J, Fernandes A, Stevens V, **Brixner D**, Stenhjem D. Characteristics of platinum-sensitive recurrent ovarian cancer patients by BRCA status in an academic cancer center. [Poster] AMCP 2014 Nexus Meeting. Boston, MA. October 7-10, 2014.
67. Jiao T, **Brixner D**. Cost Effectiveness Analysis of the Threshold for Initial Hypertension Treatment- A Markov Study Following the JNC8 Guideline. [Poster] ISPOR 19th Annual International Meeting. Montreal Canada. May 31-Jun 4, 2014.
68. Stenhjem D, Bellows BK, Kaldate RR, Jones J, Siebert U, **Brixner D**. Cost-effectiveness of using a prognostic test to guide treatment decisions in early stage non-small cell lung cancer (NSCLC). [Poster] ISPOR 19th Annual International Meeting. Montreal Canada. May 31-Jun 4, 2014.
69. Kuo K, Stenhjem D, Kluibenschädl M, Rochau U, Brixner D. Quality of life outcomes of the us chronic myeloid leukemia (CML) patients. [Poster] ISPOR 19th Annual International Meeting. Montreal Canada. May 31-Jun 4, 2014.
70. Stenhjem DD, Bellows BK, Kaldate R, Jones JT, Siebert U, **Brixner DI**. A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis. [Poster] American Society of Clinical Oncology Meeting. Chicago, Illinois. May 30-June 3, 2014.

71. McAdams-Marx C, Bellows BK, Wygant GD, Mukherjee J, Unni S, Ye X, Iloeje UH, **Brixner D**. Associations between claims based adherence, weight loss and glycemic control in patients with Type 2 diabetes. [Poster] International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. New Orleans, LA. May 18-22, 2014.

## 2013

72. **Brixner DI**, Mavros P, Goodman, M, Unni S, Ye X. Prevalence Of Hypertension And Extent Of Blood Pressure Control In Patients With Chronic Kidney Disease: Evidence From Ambulatory Care Data In The US. [Poster] American Heart Association Scientific Sessions 2013. Dallas, TX. November 17, 2013.
73. Hamilton M, Biskupiak J, **Brixner DI**, Xianying P, Xianchen L, Ghate S. Oral Anticoagulant Discontinuation in Patients with Nonvalvular Atrial Fibrillation and Cardiac Surgery. [Poster] American Heart Association Scientific Sessions 2013. Dallas, TX. November 17, 2013.
74. Bash LD, Unni SK, Goodman M, Ye X, Mavros P, **Brixner D**. Treatment Characteristics And Blood Pressure Control In Hypertensive Patients With Chronic Kidney Disease: Evidence From Ambulatory Care Practice Data In The US. [Poster] American Heart Association Scientific Sessions 2013. Dallas, TX. November 17, 2013.
75. Stenhjem D, Jiao T, Rhien T, Bellows BK, Kaldate RR, Jones J, **Brixner DI**. Literature Review and Assessment to Populate a Decision-analytic Model Evaluating a Novel Prognostic in Early Lung Cancer. [Poster] ISPOR 16th Annual European Congress. Dublin, Ireland. November 2-6, 2013.
76. Rochau U, Kluibenschaedl M, Stenhjem D, Kuo KL, Jahn B; **Brixner DI**, Siebert U. U.S. Physician Survey to Populate a Decision-analytic Model For the Treatment of Chronic Myeloid Leukemia. [Poster] ISPOR 16th Annual European Congress, Dublin, Ireland. November 2-6, 2013.
77. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Conrads-Frank A, Stenhjem D, **Brixner DI**, Radich J, Gastl G, Siebert U. Uncertainty and Cost-effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. [Poster] ISPOR 16th annual European Congress, Dublin, Ireland. November 2-6, 2013.
78. Jiao T, Liou TG, Young D, **Brixner DI**. A Comparison of Demographic and Clinical Variables of Down Syndrome Patients in Utah and the United States. [Poster] ISPOR 16th Annual European Congress. Dublin, Ireland. November 2-6, 2013.
79. Udomakorn S, Stenhjem D, Welch B, Cheng Y, Anderson L, Colonna S, Neumayer L, **Brixner DI**. Evaluation of Variable Relevance and Accessibility to Support Personalized Medicine in Breast Cancer. [Poster] ISPOR 16th Annual European Congress. Dublin, Ireland. November 2-6, 2013.
80. Schall I, Saverno K, Luzak A, Mitrovic M, Gothe H, **Brixner D**, Siebert U. The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. [Poster] The Convention Centre Dublin, Ireland. November 2-6, 2013.
81. Stenhjem D, Yoo, M, Unni S, Singhal M, Bauer H, Savarno K, Quaah C, Masaquel A, **Brixner DI**. Assessment of Single-institution HER2 Testing Patterns, Rate of HER2+ Disease and Utilization of Trastuzumab in Early Breast Cancer. [Poster] ASCO's Quality Care Symposium. San Diego, CA. November 1-2, 2013.
82. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Conrads-Frank A, Stenhjem D, **Brixner DI**, Radich J, Gastl G, Siebert U. Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. [Poster] Society of Medical Decision Making 35th Annual Meeting. Baltimore, MD. October 19-23, 2013
83. Dahal A, Bellows BK, Stenhjem D, **Brixner D**. An empirical assessment of non-small cell lung cancer charges by survival. *Eur J Cancer*. 2013;49(Suppl 2):341. Poster presentation at the European Cancer Congress (ECCO) 2013, Sep 2013.
84. Bellows BK, Dahal A, Stenhjem D, **Brixner D**. The impact of survival on ovarian and non-ovarian cancer-specific health care charges during ovarian cancer treatment. *Eur J Cancer*. 2013;49(Suppl 2):248. Poster presentation at ECCO 2013, Sep 2013.
85. Rochau U, Kallinger S, Schmidt S, Saverno K, Holzner B, Schwarzer R, Arvandi M, **Brixner DI**, Gastl G, Siebert U. Cross-sectional Pilot Study to Assess the Quality of Life of Chronic Myeloid Leukemia Patients in Innsbruck Using the EQ-5D. [Poster] 16<sup>th</sup> Academic Conference of the Austrian Society of Public Health. City Hotel St. Pollen, Austria. June 19-20, 2013

86. McAdam-Marx C, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Liberman JN, Iloeje U, **Brixner DI**. Association of >5% Weight Loss and Self-Reported Adherence with 6-Month Glycemic Control in Type 2 Diabetes Mellitus (T2DM): the DELTA Study.[Poster] American Diabetes Association's 73th Scientific Sessions. Chicago, IL. June 21-25, 2013.
  87. **Brixner DI**, Bellows BK, Dahal A, Stenehjem DD. Impact of survival on health care charges during melanoma treatment. *J Clin Oncol*, May 2013;31(15\_suppl):e20043. [Printed abstract]
  88. Stenehjem DD, Dahal A, Bellows BK, **Brixner DI**. An empirical assessment of breast cancer treatment charges by survival status. *J Clin Oncol*. May 2013;31(15\_suppl):e11541. [Printed abstract]
  89. **Brixner DI**, Bellows BK, Dahal A, Stenehjem DD. Impact of survival on health care charges during melanoma treatment. *J Clin Oncol*, May 2013;31(15\_suppl):e20043. [Printed Abstract] 2013 ASCO Annual Meeting Proceedings
  90. McAdam-Marx C, Bellows B, Wygant G, Mukherjee J, Unni S, YeX, Iloeji U, **Brixner DI**. Associations Between Claims Based Adherence, Weight Loss and Glycemic Control in Patients with Type 2 Diabetes. [Poster] ISPOR (International Society For Pharmacoeconomics and Outcomes Research). New Orleans, Louisiana. May 18-22, 2013.
  91. Welch B, Udomaksorn S, Cheng Y, Stenehjem D, Colonna S, Kawamoto K, **Brixner DI**. Desired Attributes for a Point-of-Care Breast Cancer Clinical Dashboard Supporting Personalized Health Care. [Poster] 2013 Cleveland Clinic Personalized Healthcare Summit. Cleveland, Ohio. May 5-6, 2013.
  92. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner DI**, Gastl G, Radich J, Siebert U. Choosing a Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia under The Uncertainty of Long-term Effectiveness and Safety. [Poster] Evidence Based Medicine Conference. Berlin, Germany. March 15-16, 2013.
  93. Jiao, T, Goodman, M, **Brixner, DI**. Are Utah and United States Down Syndrome Patients Different? [Poster] Western Pharmacoeconomics Conference. University of Arizona. Tucson, Arizona. March 14-16, 2013.
  94. Chen S, Lee Y, Alas V, Angalakuditi M, **Brixner DI**. Prevalence of Undiagnosed Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus. [Poster] National Kidney Foundation Spring Meeting. Orlando, FL. April 2-6, 2013.
- 2012**
95. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner DI**, Gastl G, Radich J, Siebert U. Targeted Therapy with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Decision-Analytic Model. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
  96. **Brixner DI**, Lising A, Gothe H, Häussler B, Dragovich C. Supporting Health Care Makers (HCDMs) with Collaborative Health Technology Assessment (HTA) Tools in Making Evidence-based Decisions: The US Experience and International Needs in Europe and Globally. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
  97. Beate J, Stenehjem D, Saverno K, Cai B, Siebert W, **Brixner DI**. Preliminary Outcomes Towards a Risk-Based Microsimulation Decision-Analytical Model Based on Treatment and Cost Inputs From a Real World Cohort of Breast Cancer Patients. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
  98. McAdam-Marx C, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, Liberman JN, Lloeje U, **Brixner DI**. Association of  $\geq 3\%$  Weight Loss and Self-Reported Adherence **With** 6-Month Glycemic Control in T2DM: the DELTA\* Study. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
  99. McAdam-Marx C, Bellows B, Wygant G, Mukherjee J, Unni S, Ye X, **Brixner DI**, Lloeje U. Weight Loss of  $\geq 3\%$  of Body Weight After Initiating New Anti-diabetic Therapy is Associated With Glycemic Control at 6 Months in Patients With Type 2 Diabetes. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
  100. Saokaew S, Cai B, Kuo K, Bauer H, Albright F, **Brixner DI**, Stenehjem D. Treatment Patterns and Outcomes of Breast Cancer Patients in a Patient-centered Retrospective Research Registry. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.



101. Cai B, Saokaew S, Stenehjem D, Kuo K, Bauer H, Albright F, **Brixner DI**. Treatment Pattern and Outcomes of Ovarian Cancer Patients in a Patient-Centered Retrospective Research Registry. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
102. Kuo K, Saokaew S, Cai B, Bauer H, Albright F, **Brixner DI**, Stenehjem D. Treatment Patterns and Outcomes of Melanoma Patients in a Patient Centered Retrospective Research Registry. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
103. Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, **Brixner DI**, Gastl G, Radich J, Siebert U. Decision-analytic Model for the First-line Therapy of Chronic Myeloid Leukemia. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
104. Rochau U, Kallinger S, Schmidt S, Saverno K, Holzner B, Schwarzer R, Arvandi M, **Brixner DI**, Gastl G, Siebert U. Quality of Life Assessment of Chronic Myeloid Leukemia Patients in Austria: Cross-Sectional Pilot Study Using the EQ-5D [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
105. Jahn B, Stenehjem D, Saverno K, Rochau U, Cai B, Siebert U, **Brixner DI**. Application of Real World Data to Inform a Breast Cancer Decision-analytic Model in Austria and the U.S. – Preliminary Outcomes of Data Collection. [Poster] ISPOR 15<sup>th</sup> Annual European Congress. Berlin, Germany. November 6, 2012.
106. Hamilton, M, Liu, X, **Brixner DI**, Biskupiak J. Utilization Patterns of Anticoagulants in Non-Valvular Atrial Fibrillation after the entry of Novel Oral Anticoagulants in the United States. [Poster] American Heart Association. Los Angeles, CA. November 6, 2012.
107. Jahn B, Stenehjem D, Saverno K, Cai B, Siebert U, **Brixner DI**. Preliminary Outcomes Towards a Risk-Based Microsimulation Decision-Model based on Treatment and Cost Inputs From a Real World Cohort of Breast Cancer Patients. [Poster] The 34th Annual Meeting of the Society for Medical Decision Making. Phoenix, AZ. October 17 - 20, 2012.
108. Stenehjem D, Kuo K, Bauer H, Barney R, Albright F, **Brixner DI**. Outcomes and treatment patterns of hepatocellular carcinoma patients stratified by staging-guided treatment categories in a patient-centered retrospective research registry. [Poster] ISPOR 5th Asia-Pacific Conference. Taipei, Taiwan. September 2012.
109. Stenehjem D, Albright F, Guo A, Chen L, Raimundo K, Bauer H, **Brixner DI**. Assessing real-world response monitoring and tolerability of imatinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP) and A chart review analysis of monitoring and patterns of treatment switching in patients with chronic myeloid leukemia in chronic phase (CML-CP) on imatinib. [Poster] 14<sup>th</sup> International Conference CML- Biology and Therapy. Baltimore, MD. September 20-23, 2012.
110. Marcus RL, Ghate S, **Brixner DI**, LaStayo P. Relative Sarcopenia and Not Absolute Sarcopenia Impacts Physical Performance in Non-Obese Older Adults. [Poster] The Gerontological Society of America. Albuquerque, NM. July 12-13, 2012.
111. Saverno K, Rochau U, Schmidt S, Stenehjem D, Kallinger S, Gastl G, **Brixner DI**, Siebert U. Comparison of Chronic Myeloid Leukemia Registries in Austria and Utah, USA. [Poster] 9th Annual Meeting of Health Technology Assessment International. Bilbao, Spain. June 23-27, 2012.
112. Oderda G, Holtorf AP, **Brixner DI**. Health Economic and Outcomes Research (HEOR) Evidence in Health Technology Assessment (HTA) for Drug Formulary and Reimbursement Decisions across Global Regions. [Poster] HTAi Annual Meeting. Bilbao, Spain. June 23-27, 2012.
113. Jahn B, **Brixner DI**, Saverno K, Rochau U, Stenehjem D, Albright F, Siebert U. Application of Real World Data to Inform A Decision -Analytic Model in Breast Cancer in Austria and the U.S. [Poster] Biennial European Meeting of the Society for Medical Decision Making, 14th. Oslo, Norway. June 10-12, 2012.
114. Stenehjem D, Albright F, Saverno K, Rochau U, Siebert U, **Brixner DI**. Real World Data Inform a Decision Analytic Model in Breast Cancer in Austria and the U.S. [Poster] 14<sup>th</sup> Biennial European Meeting of the Society for Medical Decision Making (SMDE Europe 2012) Oslo, Norway, June 10 -12, 2012.
115. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Lackner M, Sroczynski G, Schall I, Schnell-Inderst P, Flatscher-Thöni M, Gothe H, Pagner K, **Brixner DI**, Siebert U. Do existing cost-effectiveness thresholds adequately support decision making for PCM? A review of international practice. [Poster] 14<sup>th</sup> Biennial European Meeting of the Society for Medical Decision Making (SMDE Europe 2012) Oslo, Norway, June 10 -12, 2012.

116. Ghate, S, Porucznik C, Said Q, Joy EA, Hashibe M, **Brixner DI**. Association Between Second Generation Antipsychotics and Changes in Body Mass Index in Adolescents. ISPOR 17<sup>th</sup> Annual International Meeting. Washington, D.C. June 4, 2012.
117. Stenehjem D, Albright D, Gou A, Chen L, Raimundo K, Bauer H, **Brixner, DI**. Real-world response monitoring and tolerability of imatinib treated chronic myeloid leukemia patients captured in a retrospective research registry. [Poster] ASCO Meeting. Chicago, IL. June 4, 2012.
118. Stenehjem D, F. Albright F, K. Kuo K, K. Raimundo K, **Brixner DI**. Evaluating Contemporary Practice in CML via a Retrospective Research Registry of Patients across a Comprehensive Cancer Center Database. International Society For Pharmacoeconomics and Outcomes Research, 17th Annual International Meeting. Washington, DC. June 1-6, 2012.
119. Dye J, Bellows B, Holtorf A, **Brixner, DI**. Use of Pharmacoeconomic and Outcomes Research in Formulary Decision Making: A Tale of Two Surveys [Poster] AMCP Meeting. San Francisco, CA. April 16-19, 2012.
120. Bellows B, McAdam-Marx C, Unni S, Ye X, Mukherjee J, **Brixner DI**. 12-month HbA1c and Weight Outcomes by Drug Class in Treatment Naïve Patients with Type 2 Diabetes. [Poster] AMCP Meeting. San Francisco, CA. April 16-19, 2012.

## 2011

121. McAdam-Marx C, **Brixner D**, Ye X, Unni S, Mukherjee J. Weight Loss, Independent of Drug Class, Predicts HBA1C Goal Attainment in Patients 65 Years and Older in a Real-World Setting. [Poster] ISPOR 14<sup>th</sup> Annual European Congress, Madrid, Spain. November 8, 2011.
122. Bron M, Bellows B, Ye X, Yu J, Rapala S, Oderda G, **Brixner DI**. Prevalence and Cost of Cardiovascular Events Predicted by Body Mass Index Risk Factors: a Decision Tree Analysis. [Poster] Obesity 2011 - the 29th Annual Scientific Meeting of The Obesity Society. October 3, 2011.
123. McAdam-Marx C, **Brixner DI**, Ye X, Unni S, Mukherjee J. Weight loss of 3% or more in a 12-month period is associated with glycaemic control in newly treated type 2 diabetes patients in the usual care setting. [Poster] 47th EASD Annual Meeting Lisbon, Portugal. September 12, 2011.
124. **Brixner DI**. Comparison of the Trends in Prevalence of Overweight among Adolescents on Antipsychotics to Non-Users from 2000 to 2009. [Poster] 27<sup>th</sup> International Conference on Pharmacoeconomics and Therapeutic Risk Management, Chicago, IL. August 14-17, 2011.
125. Bron M, Bellows B, Ye X, Yu J, Rapala S, Oderda G, **Brixner DI**. Prevalence-Adjusted Cost of Comorbidities in Overweight/Obese Patients with a Body Mass Index. [Poster] American Diabetes Association 71st Scientific Sessions, San Diego, CA. June 24-28, 2011.
126. **Brixner DI**, Bron M, Bellows B, Ye X, Harikrishnan V, Oderda G. Prevalence-Adjusted Cost of Comorbidities in Overweight/Obese Patients With a Body Mass Index 25-34.9 vs  $\geq 35$ . [Poster] ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 21-25, 2011.
127. Albright F, Bollu V, Kuo KL, Raimundo K, Barney R, Stenehjem D, **Brixner DI**. IS1: Integrating Data Source To Conduct Comprehensive Oncology Based Outcomes Research. Novartis Pharmaceuticals Corporation, ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 21-25, 2011.

## 2010

128. Kwong J, Cho S, Ghate S, **Brixner DI**, Fox E. Adverse Outcomes Following Substitution of Warfarin Products in Atrial Fibrillation Patients [Poster Presentation] 45<sup>th</sup> ASHP Midyear Clinical Meeting & Exposition, Anaheim, CA. December, 2010.
129. **Brixner DI**. Evaluation of Support Services to Colorectal Cancer Patients in Mexico [Poster Presentation] ISPOR 13th Annual European Congress, Prague, Czech Republic. November, 2010.
130. **Brixner DI**. Current and Future Use of Pharmacoeconomic and Outcomes Research Data in Decision Making in the USA. [Poster Presentation] ISPOR 13th Annual European Congress, Prague, Czech Republic. November, 2010.
131. **Brixner DI**, Oderda G. Application of Economic Evaluation Tools from the United States and Europe Toward Pricing and Reimbursement Strategies in the Asia-Pacific Region. ISPOR 4<sup>th</sup> Asia-Pacific Conference, Phuket, Thailand. August 2010.

132. **Brixner DI**, Biskupiak J, Holtorf AP. Current and Future use of Health Economic and Outcomes Research Data in Decision Making, European Society of Medical Decision Making Workshop, Tyrol, Austria. May 31, 2010.
133. Dhamane AD, Martin B, **Brixner DI**, Hudson TJ, Said Q. Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics (SGAS) Using Electronic Medical Record (EMR) Data, [Poster Presentation] ISPOR 15<sup>th</sup> Annual International Meeting. Atlanta, GA. May, 2010.
134. McAdam-Marx C, **Brixner DI**. Approach To Matching Alzheimer's Disease Patient and Their Spouses to Assess Caregiver Burden in an Administrative Claims Database. [Poster Presentation] ISPOR 15<sup>th</sup> Annual International Meeting, Atlanta, GA. May 15-19, 2010.
135. Tasic D, **Brixner DI**, Goodman MJ. The Impact of Oral Antidiabetics on Weight in the Elderly with Type 2 Diabetes Mellitus in the Ambulatory Setting. [Poster] 15<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA. May15-19, 2010.
136. **Brixner DI**. Future Trends in Using Health Economics and Outcomes Research Data in Formulary Decision Making [Round-Table] AMCP 2010 Educational Conference, St. Louis, Missouri. October, 2010.
137. **Brixner DI**, Oderda G. Application Towards Integrated Learning of the Medical Pipeline in the PharmD Curriculum. AACP Annual Meeting, Seattle, WA. July 2010.
138. **Brixner DI**. Comparing Adherence Measures Against One-Year Outcomes for Patients with Epilepsy. AMCP 22<sup>nd</sup> Annual Meeting & Showcase, [Poster] San Diego, CA. April, 2010.
139. McAdam-Marx C, Bouchard J, Aagren M, Nelson R, **Brixner DI**. Analysis of Glycaemic Control and Weight Change in Patients Initiated with Human or Analog Insulin in an US Ambulatory Care Setting [Abstract] *Diabetes, Obesity and Metabolism*, January 2010, 12(1): 54-64.

## 2009

140. **Brixner DI**. (2009) International Health Economics and Outcomes Research Advisory Board Chair Person, Copenhagen, DK. Oct. 14, 2009.
141. **Brixner DI**, Ye X, Chu Teng-Chiao, Blumentals WA, Hassaniein TI. (2009). Meta-Analysis Estimate of Number Needed to Treat (NNT) to Achieve a Composite Outcome (A1C Less Than 7 Percent, No Weight Gain and No Hypoglycemia) for Liraglutide, a Human Glucagon-Like Peptide-1 (GLP-1) Analog, Across Six Randomized Controlled Trials [Abstract] *Am J Health-Syst Pharm*, 66(Nov).
142. **Brixner DI**. Assessment of Adherence in Hypertension: A Workshop on Issues and Challenges. HTAi 6<sup>th</sup> Annual Meeting, Singapore. June 21-24, 2009.
143. **Brixner DI**, McAdam-Marx C, Nelson R, Aagren M, Bouchard J. Analysis of Glycemic Control and Weight Changes in Patients Treated with Analog Basal Insulin in a Real-World Setting. IDF 20<sup>th</sup> World Diabetes Congress, [Poster Presentation] Montreal, Canada. October 2009.
144. McAdam-Marx C, Aagren M, Bouchard J, **Brixner DI**, Yu J. Average Daily Dose of Analog Basal Insulin in Patients with Type 2 Diabetes: A Matched Case Control Analysis. IDF World Diabetes Congress, Montreal, Canada. Oct. 2009.
145. **Brixner DI**, McAdam-Marx C, Nelson R, Aagren M, Bouchard J. [Published Abstract] Analysis of Glycemic Control and Weight Changes in Patients Treated with Analog Basal Insulin in a Real-World Setting. American Diabetes Association, 69<sup>th</sup> Annual Scientific Meeting, New Orleans, LA. June, 2009.
146. Fabunmi R, McAdam-Marx C, Ye X, Misurski D, **Brixner DI**. Blood Pressure Outcomes After 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study. American Diabetes Association, 69<sup>th</sup> Annual Scientific Meeting, New Orleans, LA. June 5-7, 2009.
147. **Brixner DI**, Herrings R, Gwadry-Sridhar, Femida. Assessment of Adherence in Hypertension: A Workshop on Issues and Challenges. 6<sup>th</sup> Annual Conference Health Technology and Assessment International, Singapore. June 2009.
148. McAdam-Marx C, Yu J, Shankar V, Bouchard J, **Brixner DI**. Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes. 14<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research ISPOR, Orlando, FL. May 2009.
149. **Brixner DI**, McAdam-Marx C, X Ye, Misurski D, Wintle M, Fabunmi R. 18 Month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study. 14<sup>th</sup> Annual

International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.

150. McAdam-Marx C, **Brixner DI**, X Ye, Misurski D, Fabunmi R. A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Naïve Patients with Type 2 Diabetes in an Ambulatory Care Setting. 14<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Orlando, FL. May 2009.
151. Yu J, **Brixner DI**, Ghate S, Gordon K. A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. 5<sup>th</sup> Annual Utah Health Services Research Conference, [Podium Presentation] Salt Lake City, UT. May 2009.
152. Biskupiak JE, **Brixner DI**, Hilker R, Levy DG. Effectiveness of Amlodipine / Valsartan Single-Pill Combination Therapy in Primary Care. ACCP / ESCP International Congress on Clinical Pharmacy, Orlando, FL. April 2009.
153. **Brixner DI**, Biskupiak JE, Buysman E, Reynolds M. PRR-06: Effects on Resource Utilization of Ranolazine in the Treatment of Angina Patients in Managed Care. AMPC 21<sup>st</sup> Annual Meeting & Showcase, Orlando, FL. April 2009.

## 2008

154. **Brixner DI**. The Use of Real World Data to Assess Compliance and Economics in Hypertension. Workshop. ISPOR 11<sup>th</sup> Annual European Congress, Athens, GR. Nov. 2008.
155. **Brixner DI**, Malone, D, Watkins J. Advancing the Use of Real World Data in Formulary and Reimbursement Decision Making. AMCP 2008 Educational Conference, Kansas City, MO. October 2008.
156. Gold DT, Borisov NN, Steinbuch M, **Brixner DI**. Improvement in Quality of Life Among Women Treated with Risedronate: Experience From a 2-Year Randomized Controlled Study. ASBMR 30<sup>th</sup> Annual Meeting, Montreal, Canada. September 2008.
157. **Brixner DI**, Borisov NN, Purple C. Excess Medical Cost After a Fragility Fracture During 3-Year Follow-up. ASBMR 30<sup>th</sup> Annual Meeting, Montreal, Canada. September 2008.
158. **Brixner, DI**. The Use of Real World Data to Assess Compliance and Economics in Hypertension. Workshop. ISPOR 3<sup>rd</sup> Asia Pacific Conference, Seoul, South Korea. Sept. 2008.
159. Lafleur J, Nelson RE, McAdam-Marx C, **Brixner DI**, Ward R. Patent Extension Policies for Pediatric Indications: An Evaluation of the Impact Within One Drug Class in One State Medicaid Program. Academy Health Research Meeting, Washington, DC. June 2008.
160. Shafazand S, Yang Y, Mitsi G, **Brixner DI**. Heart Failure Quality of Care: Views From a Nationwide Administrative Claims Database. American Heart Association 9<sup>th</sup> Scientific Quality of Care Cardiovascular Disease and Stroke, Baltimore, Maryland. April/May 2008.
161. Nickman NA, Haak SW, Harald EA, Holtorf AP, Joshi AV, Kim JW, **Brixner DI**. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.
162. **Brixner DI**, McAdam-Marx C, Biskupiak J, Lau HJ, Munger M. Association of Adverse Events of Antihypertensive Therapy by Age in a Physician Practice National EMR Database. American Heart Association Quality of Care Cardiovascular Disease and Stroke, Baltimore, Maryland. April/May 2008.
163. McAdam-Marx C, **Brixner DI**, Field R, Metraux S. Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.
164. **Brixner, DI**, McAdam-Marx, C, Ye, XY, Boye, K, Fabunmi, R, Schroeder, B. Real World Six Month Outcomes of Patients Initiating Exenatide in a Primary Care Electronic Medical Record Database. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.
165. McAdam-Marx C, **Brixner DI**, Oberg B. Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 months via Electronic Medical Records. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.

166. McAdam-Marx C, **Brixner DI**, Ye X, Sung JC, Kahler KH. Evaluation of Resistant Hypertension in a Usual-Care Setting. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.
167. Ghate SR, Said Q, Huse D, Ben-Joseph R, **Brixner DI**. Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight US Primary Care Patients. 13<sup>th</sup> Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Toronto, Canada. May, 2008.
168. Hassanein TI, Ye X, Blumentals WA, **Brixner DI**. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. Digestive Disease Week, San Diego, California. May 2008.
169. McAdam-Marx C, **Brixner DI**, Asche C. Identifying Potential Adverse Events in an Electronic Medical Record Database. 4<sup>th</sup> Annual Utah Health Services Research Conference, Salt Lake City, UT. April 25, 2008.
170. Hassanein TI, Ye X, Blumentals WA, **Brixner DI**. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Phoenix, Arizona. April 2008
171. Hassanein TI, Ye X, Blumentals WA, **Brixner DI**. Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin. 43<sup>rd</sup> Annual Meeting European Association for the Study of the Liver (EASL), Milan, Italy. April 2008.
172. **Brixner DI**. Utilization of Real World Data in Decision Making. First Annual Turkey ISPOR Chapter Meeting, Antalya, Turkey. April 2008.
173. Ghate SR, Doan J, Nelson R, Van Den Bos J, **Brixner DI**. Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Phoenix, Arizona. May, 2008.
174. Nickman N, Haak S, Harald E, Holtorf AP, Joshi AV, Kim J, **Brixner DI**. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting (ISPOR), Toronto, Canada. May, 2008.
175. McAdam-Marx C, **Brixner DI**, Oberg B. Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 Month Via Electronic Medical Records. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting (ISPOR), Toronto, Canada. May 2008.
176. Said Q, Ghate S, Huse D, Ben-Joseph R, **Brixner DI**. Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight Primary Care Patients. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting (ISPOR), Toronto, Canada. May, 2008.
177. Ghate S, Said Q, Rosenblatt L, Kim E, Pikalov A, **Brixner DI**. Real-World Six Month Outcomes of Patients Initiating Exenatide in a Primary Care Electronic Medical Record Database. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting (ISPOR), Toronto, Canada. May, 2008.
178. McAdam-Marx C, **Brixner DI**, Field R, Metraux S. Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting (ISPOR), Toronto, Canada. May, 2008.
179. Ghate SR, Said Q, Rosenblatt LC, Kim E, Pikalov A, **Brixner DI**. Real World Association Between Antipsychotic Treatment and Weight Gain in an Adolescent Population. International Society of Pharmacoeconomics and Outcomes Research 13<sup>th</sup> Annual International Meeting ISPOR, Toronto, Canada. May, 2008.
180. **Brixner DI**. Workshops: Principles of Pharmacoeconomics and Efficacy to Effectiveness. ISPOR 1<sup>st</sup> International Summer School. Istanbul, Turkey. April 17, 2008.
181. **Brixner DI**. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. ISPOR 13<sup>th</sup> Annual Meeting, 2008.

2007

182. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis. American College of Gastroenterology Annual Scientific Meeting, Philadelphia, Pennsylvania. 2007.
183. Muszbek N, **Brixner DI**, Benedict A, Keskinaslan A, Khan ZM. The Economic Consequences of Noncompliance in Cardiovascular Disease and Related Conditions: a Literature Review. International Society of Pharmacoeconomics and Outcomes Research ISPOR 1<sup>st</sup> Latin America Conference, Cartagena, Columbia. 2007.
184. **Brixner DI**, Ghate SR, McAdam-Marx C, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), International Society of Pharmacoeconomics and Outcomes Research ISPOR 1<sup>st</sup> Latin America Conference, Cartagena, Columbia. 2007.
185. **Brixner DI**, Neumann PJ, White JT. Bridging the Gap Between Health Outcomes Research Information and Formulary Decisions: Utilization of the Real World Task Force Report. Academy of Managed Care Pharmacy Educational Conference. October 2007.
186. **Brixner DI**, Jackson K, Sheng X, Biskupiak J, Keskinaslan A. Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Conference, Dublin, Ireland. 2007.
187. **Brixner DI**, Jackson K, Oberg B, Keskinaslan A, Sheng X. Factors Influencing Compliance with Combination Antihypertensive Pharmacotherapy in a large US Database. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10<sup>th</sup> Annual European Congress, Dublin, Ireland. October 2007.
188. Oderda G, **Brixner DI**, Lieberman M. Comparison of EMR Data to US National Data. International Society of Pharmacoeconomics and Outcomes Research ISPOR 10<sup>th</sup> Annual European Congress, Dublin, Ireland. October 2007.
189. **Brixner DI**, Ghate SR, McAdam-Marx C, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 2<sup>nd</sup> Western Pharmacoeconomics Conference, Salt Lake City, Utah. March 2007.
190. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis [Poster] American College of Gastroenterology 2007 Annual Scientific Meeting, Philadelphia, Pennsylvania. October 2007.
191. Said Q, Rosenblatt LC, Ghate S, Whitehead R, **Brixner DI**. Real World Impact of Second-generation Antipsychotics on Weight Gain in Adolescents [Poster] Institute on Psychiatric Services, New Orleans, Louisiana. October 2007.
192. Nickman N, Haak S, PhD, Holtorf AP, Joshi A, **Brixner DI**. Time-And-Motion Evaluation of Different Growth Hormone Formulations. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10<sup>th</sup> Annual European Congress, Dublin, Ireland. October, 2007.
193. **Brixner DI**, Ghate S, McAdam-Marx C, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). International Society of Pharmacoeconomics and Outcomes Research (ISPOR) First Latin America Conference, Cartagena, Colombia. Sept. 2007.
194. Munk V, Muszbek N, **Brixner DI**, Benedict A, Keskinaslan A. The Economic Consequences of Non-Compliance in Diabetes and Cardiovascular Disease: A Review of the Literature. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) First Latin America Conference, Cartagena, Colombia. Sept. 2007.
195. LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, **Brixner DI**, Silverman S. Clinical Risk Factors for Fractures are Additive Postmenopausal Women Who Are at Risk for Fracture in a Primary Care Setting [Poster] 29<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii. September 2007.

196. Biskupiak J, **Brixner DI**, Munger M, Keskinaslan A. Effectiveness of Amlodipine Valsartan Combination Therapy in Primary Care [Poster] European Society of Hypertension, 17<sup>th</sup> European Meeting on Hypertension, Milan, Italy. June 2007.
197. Jackson K, **Brixner DI**, Oderda G, Oberg B, Sheng X, Keskinaslan A. Compliance and Economic Outcomes with Valsartan and HCTZ Combination Therapy for Hypertensive Patients [Poster] American Society of Hypertension, June 2007.
198. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence in Patients with Ulcerative Colitis [Poster] Digestive Disease Week 2007, Washington, D.C. May 2007.
199. Said Q, Ghate S, Rosenblatt L, Whitehead R, **Brixner DI**. Real World Impact of Second-generation Antipsychotics on Weight Gain in an Adolescent Population [Poster] American Psychiatric Association 160<sup>th</sup> Annual Meeting, San Diego, CA. May 2007.
200. Said Q, Gutterman E, Kim M, L'Italien G, Chen C, Whitehead R, **Brixner DI**. The Association Between Antipsychotic Treatment and Unintentional Injury in Patients Diagnosed with Psychiatric Disorder [Poster] American Psychiatric Association 160<sup>th</sup> Annual Meeting, San Diego, CA. May 2007.
201. **Brixner DI**, Magowan S, Accortt N. Prescription Refill Behavior for Nifedipine Therapy is Significantly Dependent on Medication Cost [Poster] 8<sup>th</sup> American Heart Association Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, D.C. May 2007.
202. **Brixner DI**, Horowicz-Mehler N, Stern L, Doyle J, Dolgitsler M, Hagan M, PhD. Contraceptive and Non-Contraceptive Benefits of a Levonorgestrel-Releasing Intrauterine System in a Vertically Integrated HMO. ISPOR 12<sup>th</sup> Annual International Meeting, Arlington, VA. May 2007.
203. **Brixner DI**, Said Q, Ghate S, McAdam-Marx C. Correlation of Weight to Cardiometabolic Risk as Identified by ICD-9 Diagnosis Codes and Prescriptions in Primary Care. [Presentation] ISPOR 12<sup>th</sup> Annual International Meeting, Arlington, VA. May 2007.
204. **Brixner DI**, Magowan S, Accortt N. Evaluation of Prescription Refill Patterns Based on Daily Dosing Regimen and Pill Load for Calcium Channel Blockers. [Poster] Academy of Managed Care Pharmacy 19<sup>th</sup> Annual Meeting & Showcase, San Diego, California. April 2007.
205. **Brixner DI**, Said Q, Oderda G, Kirkness C. Assessment of the Clinical Risk Factors for Cardiometabolic Risk in a National Primary Care Electronic Medical Record (EMR) Database. [Poster] Academy of Managed Care Pharmacy 19<sup>th</sup> Annual Meeting & Showcase, San Diego, California. April 2007.
206. **Brixner DI**. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Research (EMR) Database. [Poster] American College of Clinical Pharmacy 2007 Spring Practice and Research Forum, Memphis, Tennessee. April 2007.
207. LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, **Brixner DI**, Silverman S. The Risk of Clinical Vertebral Fracture for Postmenopausal Patients with Specific Combinations of Fracture Risk Factors in a Primary-Care Setting [Poster] 7<sup>th</sup> International Symposium on Osteoporosis: Translating Research into Clinical Practice, Washington, D.C. April 2007.

## 2006

208. **Brixner DI**, McAdam-Marx C, Gallwitz W, Roper M, Asche CV. Value of Reducing Vertebral Fractures in Women with Post-Menopausal Osteoporosis with Multiple Clinical Risk Factors for Fracture Based on the TOP Study. [Poster] American Society of Health-System Pharmacists 41<sup>st</sup> Midyear Clinical Meeting, Anaheim, California. December 2006.
209. LaFleur J, Asche CV, McAdam-Marx C, Alder S, Sheng X, **Brixner DI**. Postmenopausal Osteoporosis Occurrence and Fracture Rates by Age in a Primary-care Setting. [Poster] American Society of Health-System Pharmacists 41<sup>st</sup> Midyear Clinical Meeting, Anaheim, California. December 2006.
210. **Brixner DI**, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ISPOR 9<sup>th</sup> Annual European Congress, Copenhagen, Denmark. October 2006.
211. Haak S, Nickman N, Rusho W, Beck S, LaFleur J, **Brixner DI**. Joint Professional Analysis of a Novel Proton Pump Inhibitor (PPI) Dosage Form. American Association of Critical-Care Nurses, National Teaching Institute and Critical-Care Exposition, [Poster] Anaheim, California. May 2006.

212. Jackson KC, **Brixner DI**, Oderda G, Oberg B, Sheng X, Keskinaslan A. Compliance and Persistence of Fixed Dose Versus Free Dose Combination Therapy with Valsartan and HCTZ for Patients with Hypertension. ISPOR 9<sup>th</sup> Annual European Congress, Copenhagen, Denmark. October 2006.
213. McAdam-Marx C, Joish VN, **Brixner DI**, Hoblyuk R. A Comparison of Adherence and Cost of Sulfonylureas in Combination with TZDs or Metformin. P.2053-PO. [Published Abstract] ADA 66<sup>th</sup> Specific Meeting.
214. **Brixner DI**, Joish VM, McAdam-Marx C, Arondekar B, Hoblyuk R. Evaluation of Persistence and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. [Poster] AMCP 18<sup>th</sup> Annual Meeting, Seattle, Washington. April 2006.

## 2005

215. **Brixner DI**, Nickman N. Documentation of Pharmacy Cost in the Preparation of Chemotherapy Infusions in Academic and Community-Based Oncology Practices. ISPOR 8<sup>th</sup> European Congress, Florence, Italy. November 2005.
216. **Brixner, DI**. Documentation of Pharmacy Cost in the Preparation of Chemotherapy Infusions in Academic and Community-Based Oncology Practices. [Poster] International Society of Pharmacoeconomics and Outcomes Research ISPOR European Conference, Florence, Italy. October 2005.
217. Biskupiak JE, **Brixner DI**, Oderda GM, Howard K. Gastrointestinal Complications of Over-the-Counter Non-Steroidal Anti-Inflammatory Drugs. [Presentation] ACG 70<sup>th</sup> Annual Scientific Meeting, Honolulu, Hawaii. October 2005.
218. Maio V, Yuen E, **Brixner DI**, Oderda GM, Asche CV, Smith KD, Morgan S. Multi-National Assessment of Outcomes Via Retrospective Databases, Healthcare Policy Development Issues, Contributed Workshops. [Presentation] International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 8<sup>th</sup> European Congress, Florence, Italy. October 2005.
219. Joish VN, **Brixner DI**, LaFleur J, Kirkness C. Pharmacoeconomic Analysis of ARB Therapy in Patients with Mild-to-Moderate Hypertension. [Poster] Academy of Managed Care Pharmacy 2005 Educational Conference, October 2005.
220. **Brixner DI**, Corey-Lisle P, Oberg B, Tuomari V, Biskupiak JE. Complexity of Depression Treatments: Healthcare Utilization and Costs. [Presentation] APA Annual Meeting, Toronto, Canada.
221. Joish VN, Stockdale WA, Brady E, Dirani R, **Brixner DI**. An Assessment of Diagnosis and Treatment of COPD in Primary Care Via an Electronic Medical Record Database. [Poster] International Society of Pharmacoeconomics and Outcomes Research, Washington, D.C. May 2005.
222. **Brixner DI**, Ho MJ, Sauer BC, Stockdale WA. Development of an Integrated Diabetes Database Across Community Clinics and Hospitals. [Poster] International Society of Pharmacoeconomics and Outcomes Research, Washington, D.C. May 2005.
223. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. [Poster] National Osteoporosis Foundation, Sixth International Symposium on Osteoporosis, Washington, D.C. April 2005.
224. LaFleur J, Thompson CJ, Joish VN, Charland S, Oderda GM, **Brixner DI**. Adherence and Persistence with Lipid-Lowering Pharmacotherapy: Effects of the Covariates Copay and Disease Severity on Probabilities of Being Categorized as Compliant. [Poster] American College of Clinical Pharmacy 2005 Spring Practice and Research Forum and Updates in Therapeutics, Myrtle Beach, South Carolina. April 2005.
225. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. [Poster] European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Rome, Italy. March 2005.
226. Said Q, Ho MJ, Beckwith MC, **Brixner DI**. A Pharmacoeconomic Comparison of Oral Fluorquinolones for Complicated Urinary Tract Infections. [Poster] Academy of Managed Care Educational Conference, Nashville, Tennessee. October 2005.
227. **Brixner DI**. Said Q, Newcomer J, Tuomari V, Oderda GM, Stockdale W, L'Italiani GJ. Diagnostic Coding for Patients on Second Generation Anti-psychotics in Real World. [Poster] American Psychiatric Association 158<sup>th</sup> Annual Meeting, Atlanta, Georgia. May 2005.



228. Joish VN, Brady E, Stockdale WA, Dirani R, **Brixner DI**. Identification and Diagnosis of COPD in a Primary Care Setting. [Poster] International Conference American Thoracic Society Meeting, San Diego, California. May 2005.
229. Ho MJ, Sauer B, Stockdale B, **Brixner DI**. Development of an Integrated Diabetes Database Across Community Clinics and Hospitals. ISPOR 10<sup>th</sup> Annual International Meeting, Washington, DC. May 2005.
230. **Brixner DI**, Ho MJ, Sauer BC, Stockdale WA. Real World Usage of Weight Gain Drugs in Patients on Second-Generation Antipsychotics. [Poster] American Diabetes Association, June 2005.

#### 2004

231. LaFleur J, Thompson C, Ho MJ, Stockdale WA, Charland S, Oderda GM, **Brixner DI**. Adherence, Persistence, and Cost of Lipid-Lowering Pharmacotherapy: ER-Niacin/Statin Combination Therapy within a Single Dosage-Form Versus Two Separate Dosage Forms in a Managed Care Population. [Poster] Academy of Managed Care Pharmacy 2004 Educational Conference, Baltimore, Maryland. October 2004.
232. Ho MJ, LaFleur J, **Brixner DI**. Which Atypical Antipsychotics for Schizophrenia: Cost-Efficacy Versus Cost-Effectiveness Analyses. [Poster] Academy of Managed Care Pharmacy Educational Conference, Baltimore, Maryland. October 2004.
233. LaFleur J, Thompson C, Biskupiak J, Stockdale W, Oderda GM, **Brixner DI**. Compliance, Adherence, and Persistence: A Comparison of Three Methodologies for Evaluating Patient Compliance Using Prescription Claims Data. ISPOR 7<sup>th</sup> Annual European Congress, Hamburg, Germany. Oct. 2004.
234. Stockdale WA, **Brixner DI**. Comorbidity Influence Index. [Poster] International Society of Pharmacoeconomics and Outcomes Research 9<sup>th</sup> Annual Meeting, Arlington, Virginia. May 2004.
235. Joish VN, Donaldson G, Stockdale WA, Oderda GM, **Brixner DI**, Sasane R, Joshua-Gotlib S, Crawley JA. Economic Burden of GERD and PUD in an Employed Population. [Poster] International Society of Pharmacoeconomics and Outcomes Research 9<sup>th</sup> Annual Meeting, Arlington, Virginia. May 2004.
236. **Brixner DI**, Cannon HE, Oderda GM, Stockdale WA, Joish VN, Hanson D. Impact of Varying CoPays on Patient Prescribing Behavior in a Managed Care Organization: Focus on Hypertension. [Presentation] Academy of Managed Care 16<sup>th</sup> Annual Meeting and Showcase, San Francisco, California. April 2004.
237. Christensen RL, LaFleur J, Ho MJ, Joish VN, **Brixner DI**. Which HMG-CoA reductase Inhibitor for Hyperlipidemia: a Cost-Effectiveness Analysis Based on the STELLAR Trial [Poster] Academy of Managed Care 16<sup>th</sup> Annual Meeting and Showcase, San Francisco, California. April 2004.
238. Ho MJ, Joish VN, LaFleur J, Christensen RL, **Brixner DI**. Which Oral Triptan for Migraine: a Cost-Efficacy Analysis From a Managed Care Perspective [Poster] Academy of Managed Care 16<sup>th</sup> Annual Meeting and Showcase, San Francisco, California. April 2004.
239. **Brixner DI**, Asche C, Chang J, Stewart J, Paladino JA. Economic Value of Telithromycin Vs. Clarithromycin in the Treatment of Community-Acquired Pneumonia. [Poster] 39<sup>th</sup> American Society of Health-System Pharmacists Midyear Clinical Meeting, Orlando, Florida. December 2004.

#### 2003

240. Oderda LH, Stockdale WA, Oderda GM, Donaldson G, Ashburn M, **Brixner DI**, Lipman AG. Age and Gender-Stratified Differences in Quality of Life in Elderly Chronic Pain Patients. [Poster] International Society of Pharmacoeconomics and Outcomes Research Spring Meeting, Arlington, Virginia. May 2003.
241. **Brixner DI**, Avey SG, Malone D. Practical Decision Analysis for the Decision Maker. [Presentation] International Society of Pharmacoeconomics and Outcomes Research Spring Meeting, Arlington, Virginia. May 2003.
242. Oderda GM, Gunning KM, LaFleur J, Stockdale WA, Tyler LS, Parke D, **Brixner DI**. Reviews of Utah Medicaid High Utilizers to Control Drug Costs. [Poster] International Society of Pharmacoeconomics and Outcomes Research Spring Meeting, Arlington, Virginia. May 2003.
243. **Brixner DI**, Cannon HE, Oderda GM, Biskupiak JE, Stockdale WA, Joish VN, Hanson D. Impact of Varying Co Pays on Patient Prescribing Behavior in a Managed Care Organization; Preliminary Results. [Presentation] Academy of Managed Care Pharmacy 15<sup>th</sup> Annual Meeting, Minneapolis, Minnesota. April 2003.
244. **Brixner DI**, Tabb K. Overview of Database Used in Managed Care Research. [Presentation] Academy of Managed Care Pharmacy 15<sup>th</sup> Annual Meeting, Minneapolis, Minnesota. April 2003.

245. Gunning KM, Oderda GM, Stockdale WA, LaFleur J, Orlando PL, Steinvort C, Dang K, Tyler LS, **Brixner DI**. Controlling Utah Medicaid Drug Spending Through a Regimen Review Program. [Poster] American College of Clinical Pharmacy, Orlando, Florida. April 2003.

## 2002

246. **Brixner DI**, Todd W. Compliance and Persistency Programs as a Component of Disease Management Programs in Managed Care. [Presentation] Academy of Managed Care Pharmacy 14<sup>th</sup> Annual Meeting, Salt Lake City, Utah. April 2002.

## 1999-1990

247. **Brixner DI**, Shoheiber O, Polino C, Lin C. Analysis of Compliance Across Four Therapeutic Drug Classes in a Pharmacy Claims Database. [Poster] Academy of Managed Care Pharmacy 9<sup>th</sup> Annual Meeting, New Orleans, Louisiana. May 1997.
248. **Brixner DI**, Sasane R, Goodwin W. Step Analysis of Patients Initiated on ACEI or CCB Therapy in a Managed Care Setting. [Poster] Academy of Managed Care Pharmacy 9<sup>th</sup> Annual Meeting, New Orleans, Louisiana. May 1997.
249. Duchane J, **Brixner DI**, Growboski B, Gunter M. Identification of Patients with Seizure Disorders in a Managed Care Setting. Association of Pharmacoeconomics and Outcomes Research, Washington, D.C.
250. **Brixner DI**, Holtorf AP. Pharmaceutical Manufacture's Role in Disease Management. [Presentation] University of Arizona Conference: Disease Management – Fact or Fantasy, Tucson, AZ.
251. **Brixner DI**, Lauper P. Global Pharmacoeconomics: Impact on the US Managed Care Market. [Presentation] Academy of Managed Care Pharmacy Academy of Managed Care Pharmacy 7<sup>th</sup> Annual Meeting, Tampa, Florida. May 1995.
252. Demarinis RM, Little A, Health Economic Group, **Brixner DI**. Economic Analysis of Nabumetone, Ibuprofen, and Combination Ibuprofen and Misoprotol in the Treatment of Elderly Patients with Osteoarthritis; Academy of Managed Care Pharmacy 6<sup>th</sup> Annual Meeting, Chicago, Illinois. May 1994.
253. Demarinis RM, Little AD, Health Economic Group, Schainbaum S, **Brixner DI**. Economic Analysis of Paroxetine vs. Imipramine in the Treatment of Depressed Outpatients; [Poster] California Society of Hospital Pharmacists Annual Meeting. San Francisco, CA.
254. Demarinis RM, Arthur D. Little Health Economic Group, **Brixner DI**. Economic Analysis of Nabumetone, Ibuprofen, and Combination Ibuprofen and Misoprotol in the Treatment of Elderly Patients with Osteoarthritis; [Poster] Hawaii Society of Hospital Pharmacists Annual Meeting.
255. Riker K, **Brixner DI**, Priest J, Woodle D, Hammond L, Srinivasan A, Fitzberg AL, Morgan AC Jr. Disulfide Immunoconjugates of 6MP Using the Drug's Intrinsic Thiol.
256. Rao TN, **Brixner DI**, Kasina S, Srinivasan A, Wester DW, Vanderheyden JL, Fritzberg AR. Synthesis and Stability Evaluation of Small Molecule Hydrazones Toward Therapeutic Immunoconjugates.

## 1989-1980

257. Wester DW, Rao TN, **Brixner DI**, Srinivasan A, Kasina S, Fitzberg AR. Synthesis and Characterization of the Tc-99 Complex of a Complex of a Bifunctional Ligand Used for Protein Labeling.
258. **Brixner DI**, Broom AD. N-10-Thymidylyl-8-Deazafolate as a Mechanistic Probe of the Thymidylate Synthetase Reaction.
259. **Brixner DI**, Broom AD. Approaches Toward Pyridine Ring Reduction in the Convergent Syntheses of a Multisubstrate Inhibitor of Thymidylate Synthetase.
260. Kuehl M, Avery T, **Brixner DI**, Broom AD, Newton PA, Blakley DL. Evaluation of the Non-Hydroxylatable Antifolates 8-Deaza-Methotrexate (8-DMTX) and 8-Deazaaminopterin (8-DAMT) and Comparison with Methotrexate (MTX) and Aminopterin (AMT).
261. **Brixner DI**, Bayomi S, Eissa H, Broom AD. Novel Active Site Probe of Thymidylate Synthetase.
262. **Brixner DI**, Broom AD. Synthesis of N10-Alkyl-Substituted Multisubstrate Inhibitors of Thymidylate Synthetase.
263. **Brixner DI**, Broom AD. Synthesis of N10-propargyl Derivatives of 8-Deazafolate and 8-Deazaaminopterin.

## D. Patents/Copyrights

Sivam G, Reed MW, Srinivasan A, Morgan AC, **Brixner DI**, Vrudhula VM, Comezoglu FT: Targeting Substance - Diagnostic - Therapeutic Agent Conjugates Having Schiff Base Linkages. Patent No. 5549883, 1996.

## IX. INVITED ORAL PRESENTATIONS / TRAINING SESSIONS / WORKSHOPS

### International

- 2018 **Brixner DI**. Value Based Decision Making in Public Health. The Use of Multicriteria Decision Analysis Across the World. [Presentation] Improving the Insurance System for Outpatient Services: Value Based Decisions. Beijing, China. September 14, 2018.
- Brixner DI**. Value-Based Decision Making in Developing Countries: Multi-Criteria Decision Analysis (MCDA) for Off-patent Pharmaceuticals. [Symposia] ISPOR Asia Pacific 2018, Tokyo, Japan. September 8-11, 2018.
- Brixner DI**. The Application of Indication Based Pricing to Regenerative Medicine Therapies: An Interactive Workshop. [Workshop] ISPOR Asia Pacific 2018, Tokyo, Japan. September 8-11, 2018.
- Brixner DI**. A Value Based Framework for Off-Patent Pharmaceutical Review (EFOR) in Developing Countries. [Presentation] HTAi 2018 Annual Meeting, Vancouver, Canada. June 1-5, 2018.
- Brixner DI**. Off-Patent Pharmaceuticals in Developing Countries: A Case for Multi-criteria Decision Analysis. [Presentation] HTAi 2018 Annual Meeting, Vancouver, Canada. June 1-5, 2018.
- Brixner DI**. Are Payers Equipped to Assess the Unique Value of Precision and Personalized Medicine (PPM)? Analyzing Current Value Frameworks and their Application within the PPM Context. [Workshop] ISPOR 23<sup>rd</sup> Annual International Meeting, Baltimore, MD. May 19-23, 2018.
- Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 23<sup>rd</sup> Annual International Meeting, Baltimore, MD. May 19-23, 2018.
- 2017 **Brixner DI**. Are Payers Equipped to Assess the Unique Value of Precision and Personalized Medicine (PPM)? Analyzing Current Value Frameworks and their Application within the PPM Context. [Workshop] ISPOR 22<sup>nd</sup> Annual International Meeting, Boston, MA. May 20-24, 2017.
- Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 22<sup>nd</sup> Annual International Meeting, Boston, MA. May 20-24, 2017.
- 2016 **Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 7<sup>th</sup> Asia-Pacific Conference. Sept. 3-6, 2016.
- Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 21<sup>st</sup> Annual International Meeting, Washington, DC. May 21-25, 2016.
- Brixner DI**. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology [Presentation]. Health Technology Assessment international 2016 Annual Meeting. Tokyo, Japan. May 10-14, 2016.
- Brixner DI**. Global Efforts Toward HTA of Regenerative Medicines and Cell Therapies [Presentation]. Health Technology Assessment international 2016 Annual Meeting. Tokyo, Japan. May 10-14, 2016.
- 2015 **Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 20<sup>th</sup> Annual International Meeting, Philadelphia, PA. May 16-20, 2016.
- Brixner DI**. Invited Lecturer. University of Otago. Dunedin, New Zealand. February 19-25, 2015.
- 2014 **Brixner DI**. Using Weighted Criteria For Making Decisions On Off-Patent Medicines: Case Studies From China, Thailand And Vietnam. [Workshop Presentation] ISPOR 6th Asia-Pacific Conference. Beijing, China. September 6-9, 2014.
- Brixner DI**. Evaluation Of The Barriers And Opportunities Of Big Data In Health Outcomes Research. [Workshop Presentation] ISPOR 19th Annual International Meeting. Montreal Canada. May 31-Jun 4, 2014.
- Brixner DI**. Applications in Using Large Databases. [Short Course] ISPOR 19th Annual International Meeting. Montreal Canada. May 31-Jun 4, 2014.

- Brixner DI.** Personalized Medicine And Applying Economics Models In Personalized Medicine. [Workshop Presentation] 1st ISPOR Indonesia Conference. Bali, Indonesia. May 24-27, 2014.
- 2013 **Brixner DI.** Sustainability of Off-patent Drug Policies in the Quest for Value. [Workshop Presentation] ISPOR 16th Annual European Congress. Dublin, Ireland. November 2-6, 2013.
- Brixner DI.** Will Generic Use Policy Stand up to Resilience? [Workshop Presentation] 16<sup>th</sup> European Health Forum Gastein, Bad Hofgastein, Austria. October 2-4, 2013.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 18<sup>th</sup> Annual International Meeting. New Orleans, LA. May 18-22, 2013.
- 2012 **Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 17<sup>th</sup> Annual International Meeting. Washington, DC. June 2-6, 2012.
- 2011 **Brixner DI.** Use of Real World Data in Decision Making for Global Reimbursement, Novo Nordisk, Zurich Switzerland. Aug. 2011.
- Brixner DI,** Biskupiak J. Application of Real World Databases In the U.S.; AGENS meeting (Working Group on the Use of Secondary Data) University for Health Sciences, Medical Informatics and Technology; Hall in Tirol, Austria. July 2011.
- Brixner DI.** Health Economics Modeling, Multiple Sclerosis Market Access Workshop, Advisory Board Member, London, UK. July, 2011.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 16<sup>th</sup> Annual International Meeting. Baltimore, MD. May 21-25, 2016.
- Brixner, DI,** Sweet B. Formulary Management Knowledge Clinic. Synopsis: A Discussion on the Methods used for Health Technology Assessment (HTA) in Other Countries with a Review of the AMCP Format for Formulary Submission, Version 3.0 and its use in the United States, Abu Dhabi, UAE. March 4, 2011.
- Brixner DI.** Use of Health Economics Outcomes Research Evidence Toward Market Access of Health Technology. 1<sup>st</sup> Annual Health Economic Middle East Forum, Abu Dhabi, UAE. March 3, 2011.
- Brixner DI.** Healthcare and Economics. Oman Reimbursement Systems Workshop Global Advisory Board, Oman, UAE. February 28, 2011.
- 2010 **Brixner DI.** Oderda G, Healthcare and Economics – Educating Researchers and Health-Care Policy Makers Regarding the Value of Providing Medicines. Asian Health Economics Training Workshop, Jakarta, Indonesia. Sept. 2010.
- Brixner DI,** Biskupiak J, Holtorf AP. Current and Future use of Health Economic and Outcomes Research Data in Decision Making, European Society of Medical Decision Making Workshop, Tyrol, Austria. May 31, 2010.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 15<sup>th</sup> Annual International Meeting. Atlanta, GA. May 15-19, 2010.
- Brixner DI.** U.S. Primary Care Practice Electronic Medical Record Database: GE Centricity. [Short Course] ISPOR 15th Annual International Meeting, Atlanta, GA. May, 2010.
- Brixner DI.** Healthcare and Economics, Educating Researchers and Health-Care Policy Makers Regarding the Value of Providing Medicines. 2<sup>nd</sup> Global Health Care Summit, Dubai, UAE. May 4, 2010.
- Brixner DI,** Oderda G. Healthcare and Economics, Educating Researchers and Health-Care Policy Makers Regarding the Value of Providing Medicines. Asian Health Economics Training Workshop, Jakarta, Indonesia. Jan. 14, 2010.
- 2009 McAdam-Marx C, Aagren M, Bouchard J, **Brixner DI,** Yu J. Average Daily Dose of Analog Basal Insulin in Patients with Type 2 Diabetes: A Matched Case Control Analysis. IDF World Diabetes Congress, Montreal, Canada. Oct. 2009.
- Brixner DI.** Health Economics Modeling, Multiple Sclerosis Market Access Workshop, Advisory Board Member, London, UK. Sept 18, 2009.

- Brixner DI.** Invited Speaker at Global Health Economics Ad Board for Liraglutide, Copenhagen, DK. April 28-30, 2009.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 14<sup>th</sup> Annual International Meeting. Orlando, FL. May 16-20, 2009.
- Brixner DI.** Applications In Using Large Databases. [short course] ISPOR 14<sup>th</sup> Annual International Meeting, Orlando, Florida. May, 2009.
- 2008 **Brixner DI.** Bayer HealthCare: Global Health Economics and Outcomes Research Network Conference, Berlin, Germany. Dec. 10, 2008.
- Brixner DI.** Pharmacoeconomics in Value Based Decision Making Training Course for Bayer Healthcare Executives Guatemala. June 2008. Seoul, Korea. September 2008, Berlin, Germany. December 2008.
- Brixner DI.** Bayer HealthCare: Global Health Economics and Outcomes Research Network Conference, Berlin, Germany. Dec. 10, 2008.
- Brixner DI.** The Use of Real World Data to Assess Compliance and Economics in Hypertension. Workshop. ISPOR 11<sup>th</sup> Annual European Congress, Athens, Greece. November 2008.
- Brixner DI.** Pharmacoeconomics in Value Based Decision Making Training Course for Bayer Healthcare Executives Guatemala. June 2008. Seoul, Korea. September 2008, Berlin, Germany. December 2008.
- Brixner DI.** The Value of ISPOR to its Membership: Global & Local Perspectives. ISPOR South Africa 1<sup>st</sup> Annual Congress, Pretoria, South Africa. Aug. 18, 2008.
- Brixner DI.** Pharmacoeconomics Basic and Advanced Short Courses First Annual South African ISPOR Chapter Meeting, Johannesburg, South Africa. August 2008.
- Brixner DI, Oderda G.** Health Economics and Outcomes Research, Latin America LA/LT Training Meeting, Guatemala, Mexico. May 20, 2008.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 13<sup>th</sup> Annual International Meeting. Toronto, Canada. May 3-7, 2016.
- Brixner DI.** Applications In Using Large Databases. [short course] ISPOR 13<sup>th</sup> Annual International Meeting, Toronto, Canada. May, 2008.
- 2007 **Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 12<sup>th</sup> Annual International Meeting. Arlington, VA. May 19-23, 2007.
- Brixner DI.** Real World Data in Healthcare Decision Making. European Science Foundation Conference on the Global Health Economy, Kiel, Germany. May 2007.
- Brixner DI.** Utilizing Large Databases in Outcomes Research [short course] ISPOR 12<sup>th</sup> Annual International Meeting. Arlington, VA. May 2007.
- 2006 **Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 11<sup>th</sup> Annual International Meeting. Philadelphia, PA. May 20-24, 2006.
- 2005 **Brixner DI.** Electronic Medical Records in Outcomes Research: The New Frontier. [short course] Jefferson Medical College, Philadelphia, PA. June, 2005.
- Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 10<sup>th</sup> Annual International Meeting. Washington, DC. May 15-28, 2005.
- 2004 **Brixner DI.** Applications in Using Large Databases. [Short Course] ISPOR 9<sup>th</sup> Annual International Meeting. Arlington, VA. May 16-19, 2004.
- 1995 **Brixner DI.** Monoclonal Antibodies in the Changing Health Care Environment. International Congress of Pharmaceutical Biotechnology, Ghent, Belgium. 1995.

## National

- 2018 **Brixner DI.** The Landscape of Precision Medicine in managed Care: Clinical Utility to Evidence Requirements. [Workshop] AMCP Nexus 2018, Orlando, FL. October 22-25, 2018.
- 2017 **Brixner DI.** Multiple Criteria Decision Analysis: Potential Implications to Formulary Decision-Making [Moderator], Academy of Managed Care Pharmacy (AMCP), Dallas, TX. October 19, 2017.
- Brixner DI.** Practical Experiences with Value-Based Contracts. [Panelist] AMCP Partnership Forum on Value-Based Contracting, Washington, DC. June 20-21, 2017.
- 2016 **Brixner DI.** Biomarkers and Treatment Decision-Making: Focus on Rheumatoid Arthritis. [Short Course] Academy of Managed Care Pharmacy (AMCP) 2016 Nexus Meeting. National Harbor, MD. October 3-6, 2016.
- Brixner DI.** The Promise and the Challenge of Personalized Medicine for Managed Care [Moderator], Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2016, National Harbor, MD. Oct. 3-6, 2016.
- Brixner DI.** Perspectives in Assessing the Value of Emerging Therapies [Presentation], Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2016, San Francisco, CA. April 19-22, 2016.
- 2015 **Brixner DI.** Application of Big Data to Improve the Quality of Care in Oncology, Big Data Webcast, webinar available December 2015.
- Brixner DI.** Perspectives on the Uncertainty of Drug Pricing, BioUtah Healthcare Summit Panel Discussion, Salt Lake City, UT. October 6, 2015.
- Brixner, DI.** Companion Diagnostics in Drug Therapy, Academy of Managed Care Pharmacy (AMCP) 2015 Nexus Orlando, Orlando, FL. October 26-29, 2015.
- 2014 **Brixner DI, Malone D, Sherwin C.** Utilizing Comparative Effectiveness and/or Patient-Centered Outcomes Research (CER/PCOR) on the Effects of Healthcare Interventions. ACCP Inaugural Webinar. August 27, 2014.
- Brixner DI.** AAPS Pre-symposium for the Skaggs Biomedical Research Symposium. Missoula, MT. August 14-15, 2014.
- 2013 **Brixner DI.** When Specialty Pharmacy Meets Personalized Medicine. [Continuing Education Session] AMCP 2013 Nexus, San Antonio, TX. October 18, 2013.
- Brixner DI.** Data Consortia: Answering Tomorrow's Questions Today. [Presentation] AMCP 2013 Nexus, San Antonio, TX. October 17, 2013.
- Brixner DI.** Using Large Health Care Databases for Research. [Continuing Education Session] AMCP 2013 Nexus, San Antonio, TX. October 16, 2013.
- Brixner DI.** AMCP Foundation Symposium. HTA Outside the US. [Moderator] AMCP 2013 Nexus, San Antonio, TX. October 15, 2013.
- Singhal M, **Brixner DI.** Application of Real World Data in Alzheimers Disease. [Presentation] Alzheimer's Association Research Roundtable in Washington, DC. April 15-16, 2013.
- Brixner, DI.** The Realistic Role of CER for Enhanced Decision-Making. Academy of Managed Care Pharmacy 25<sup>th</sup> Annual Meeting and Expo. San Diego, CA. April 5, 2013.
- Brixner, DI.** How Personalized Medicine is Changing the Paradigm for Establishing Value Using Real World Data. Academy of Managed Care Pharmacy 25<sup>th</sup> Annual Meeting and Expo. San Diego, CA. April 4, 2013.
- 2012 Ghatge S, **Brixner DI.** Predictors of Monitoring of Metabolic Parameters in Adolescents on Antipsychotics. 165<sup>th</sup> APA Annual Meeting, Philadelphia, PA, May 5, 2012.
- Brixner DI.** Adherence: The Key to Success for Gout Treatment. AMCP 24<sup>th</sup> Annual Meeting and Expo, San Francisco, CA. April 19, 2012.
- 2011 **Brixner DI.** Drug Information Used in the Managed Care Pharmacy P&T Decision Making Process; Current practice and Insights. AMCP and ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 24, 2011.

- McAdam-Marx C, Hane CA, Biskupiak J, Deniz B, McGarry L, **Brixner DI**. IN3: Costs Associated with HCV and Related Complications in the US from a Managed Care Payer's Perspective. ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 23-27, 2011.
- McAdam-Marx C, Ye X, Bouchard J, Aagren M, Conner C, **Brixner DI**. Bootstrapping Used to Provide Robust Mean and Variance Estimates for Comparing Patients Treated with Liraglutide to a Large Comparison Cohort. ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 23-27, 2011.
- Albright F, Bollu V, Kuo KL, Raimundo K, Barney R, Stenehjem D, **Brixner DI**. Integrating Data Source To Conduct Comprehensive Oncology Based Outcomes Research. Novartis Pharmaceuticals Corporation, ISPOR 16<sup>th</sup> Annual International Meeting, Baltimore, MD. May 23-27, 2011.
- 2009 **Brixner DI**, McAdam-Marx C, Ye X, Misurski D, Wintle M, Fabunmi R. 18 Month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type-2 Diabetes in a Real-World Study. ISPOR 14<sup>th</sup> Annual International Meeting, Orlando, Florida. May. 2009.
- Brixner DI**. Guidelines for Research Using "Real World Data". Enhancing the Rigor and Utility of Medication Use Research A Consensus Development Conference. Rockville, MD. Co-sponsored by AACP, PPRA, ISPOR, and USP. January 2009.
- 2007 **Brixner DI**. The Prevalence and Burden of Migraine and Its Impact on Managed Care. Academy of Managed Care Pharmacy 19<sup>th</sup> Annual Meeting and Showcase, San Diego, CA.
- 2006 **Brixner DI**. Pharmacoeconomics of COPD Management. American Society of Hospital Pharmacists Mid-year Meeting, Anaheim, California.
- Brixner DI**. Assessment of Cardiometabolic Risk in a Primary Care Electronic Medical Database. Academy of Managed Care Pharmacy Meeting, Seattle, Washington.
- Brixner DI**. Developing and Implementing Pharmacy Policy for Insomnia Therapies within Managed Care Plans. Academy of Managed Care Pharmacy Meeting, Seattle, Washington.
- 2005 **Brixner DI**. The Case Against Excessive Cost Sharing for Biologics. AMCP Symposium, Nashville, TN.
- Brixner DI**. Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real World Setting. AMCP Symposium, Nashville, TN.
- Brixner DI**. Electronic Medical Records in Outcomes Research: The New Frontier. Jefferson Medical College, Philadelphia, PA.
- Brixner DI**. Improving Outcomes in the Treatment of Lower Respiratory Tract Infections AMCP Framework on Quality Drug Therapy. AMCP Annual Meeting, Denver, Colorado.
- Brixner DI**. Managing Your Osteoporosis Formulary to Maximize Bone Strength and Minimize Fracture. AMCP Annual Meeting, Denver, Colorado.
- 2004 **Brixner DI**, Jorgenson J. Relationship Between Health Systems and Colleges of Pharmacy; AACP-Sponsored Program at the ASHP Midyear Clinical Meeting.
- Brixner DI**. Managing the Continuum of Treatment: Modeling the Economic Impact of Treating Diabetes. Symposium in conjunction with the Academy of Managed Care Pharmacy.
- 2003 **Brixner DI**. Patient Management in Irritable Bowel Syndrome, American Society of Health System Pharmacists Midyear Meeting. ISPOR 8<sup>th</sup> Annual International Meeting, Arlington, Virginia. May 2003.
- Brixner DI**. The Management of COPD in Managed Care Systems, Pre-Meeting Symposium to the Academy of Managed Care Pharmacy.
- Brixner DI**. The Economics of Insomnia, Pre-Meeting Symposium to the Academy of Managed Care Pharmacy.
- Brixner DI**. Utilization of the AMCP Format in Medicaid, Medicaid & Medicare, the Changing Landscape.
- 2001 **Brixner DI**. Migraine Matters: Relieving the Burden in Managed Care, Symposium in Conjunction with the Academy of Managed Care Pharmacy.

## Local

- 2015 **Brixner DI.** Benchmarking Antibiotic Use Across Three CTSA Institutions: An Update on the Challenges and Opportunities. PPH and CCTS Pilot Award Symposium: A Showcase of Current Interdisciplinary and Translational Research. University of Utah, Salt Lake City, UT. December 2, 2015.
- 2013 **Brixner DI.** Health Care Transformation Scientific Advisory Board and Symposium. [Presentation] “Driving Health Care Transformation.” Park City, UT. October 20-23, 2013.
- Brixner DI.** Health System Innovation and Research (HSIR) Program. [Presentation] Personalized Health Care Research in Utah: Opportunities, Resources, Collaborations. University of Utah, Salt Lake City, UT. April 19, 2013.
- Brixner DI.** Value Assessment of Technology: (CRAM) Clinical Research and Methods. [Presentation] The Pharmacotherapy Outcomes Research Center, College of Pharmacy. University of Utah, Salt Lake City, UT. February 20, 2013.
- 2012 **Brixner DI.** Personalize Health Care November 26, 2012 Meeting. [Presentation] Panel Discussion: Outcomes and Cost Effectiveness in Personalized Health Care. University of Utah, Salt Lake City, UT. November 26, 2012.
- Brixner DI.** Department of Family and Preventive Medicine Grand Rounds. [Presentation] Decision Modeling, Outcomes Research and Health Technology Assessment: Experiences from my Austrian Sabbatical. University of Utah, Salt Lake City, UT. May 3, 2012.
- BrixnerDI.** Personalized Health Care Research Opportunities. [Presentation] University of Utah, Salt Lake City, UT. April 30, 2012.
- Brixner DI.** Presentation to the University of Utah President’s National Advisory Council on Pioneering Outcomes in Personalized Medicine at the University of Utah. [Presentation] Salt Lake City, UT. April 13, 2012.
- Brixner DI.** Using Real World Data (RWD) to Assess the Value of New Technology for Patients. [Presentation] Health Care Reform and Health Services Research Symposium. University of Utah, Salt Lake City, UT. April 12, 2012.
- Brixner DI.** Pioneering Outcomes in Personalized Medicine at the University of Utah. [Presentation] University of Utah, Park City Institute. Park City, UT. April 11, 2011.
- Brixner DI.** Real World Data in Health Care Decision Making. [Presentation] University of Utah, Salt Lake City, March 2012.
- Biskupiak J, Ghate S, **Brixner DI.** Impact of Generic Warfarin Switching on Outcomes in Afib Patients and the Cost of Bleeding, Renal Outcomes in Afib Patients, Predictors of Adherence in Afib Patients, Afib presentation to CARMA. [Presentation] University of Utah School of Medicine, Salt Lake City Utah. January, 2012.
- 2011 **Brixner DI.** “Pharmacotherapy Outcomes Research: Application in Pediatrics”, Intermountain Primary Children’s Medical Center Grand Rounds, January, 2011.
- 2007 Holtorf AP, LaFleur J, Servatius D, Jeffries B, McBeth C, **Brixner DI.** Statin Treatment of Diabetic Patients in Utah Medicaid. Utah Health Services Research Conference: Utah Health Services Research Meets Public Health Informatics, Salt Lake City, Utah.
- 2006 **Brixner DI** (presenter), Joish VN, McAdam-Marx C, Arondekar B, Hoblyuk R. Evaluation of Persistency and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. 2nd Annual Health Services Research Conference.
- 2005 **Brixner DI** (presenter). Update on the Department of Pharmacotherapy at the University of Utah. Utah Pharmacists Association Annual Meeting, St. George, Utah.
- 2003 Oderda G, Gunning K, LaFleur J, Stockdale W, Tyler L, Parke D, Orlando P, **Brixner DI.** Reviews of Utah Medicaid High Utilizers to Control Drug Costs, Medicaid Summit.